D

APPENDIX D

Evaluation of the Influence of 12 Heparinoid Derivatives on Thrombin Generation

Laboratoire
LCL
RECHERCHE CLINIQUE

EVALUATION OF THE INFLUENCE OF 12 HEPARINOID DERIVATIVES ON THROMBIN GENERATION

J. Busson
Chief Technologist

A. Oursin
Clinical Research Director

F. Depasse
Pathologist

Prof. MM. Samama
Professor Emeritus of Hematology

STRICTLY CONFIDENTIAL

COVINGTON & BURLING

1201 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20004-2401
TEL 202.662.6000
FAX 202.662.6291
WWW.COV.COM

WASHINGTON
NEW YORK
SAN FRANCISCO
LONDON
BRUSSELS

3134 '04 FEB 20 P3:01

February 20, 2004

BY HAND DELIVERY

Dockets Management Branch (HFA-305)
Food and Drug Administration
Department of Health and Human Services
5630 Fishers Lane, Room 1061
Rockville, Maryland 20852

Re: **03P-0064/SUPP 1**

Ladies and Gentlemen:

On February 12, 2004, on behalf of Aventis Pharmaceuticals Inc. ("Aventis"), we filed a supplement (the "Supplement") to Aventis' Citizen Petition of February 19, 2003 (03P-0064/CP1). We understand that FDA filed the Supplement to that docket as 03P-0064/Supp 1.

The Supplement contains several reports of preclinical studies, included as Appendices A through I. Several pages of those reports bear "confidential" or "strictly confidential" stamps. Please be advised that these stamps should have been removed prior to submission of the Supplement, and are included on those documents in error. Aventis does not consider this material to be confidential at this time. Therefore, on behalf of Aventis, we request that you treat all of the materials accompanying the Supplement as non-confidential material.

Thank you for your attention to this matter. Please do not hesitate to contact me should you have any questions. Thank you.

Sincerely,

Peter O. Safir

Laboratoire
LCL

EVALUATION OF THE INFLUENCE OF 12 HEPARINOID DERIVATIVES ON THROMBIN GENERATION

J. Busson
Chief Technologist

A. Oursin
Clinical Research Dept Director

F. Depasse
Pathologist

Prof. MM. Samama
Professor Emeritus of Hematology

Introduction:

The biological evaluation of the potential anticoagulant effect of new drugs is based on coagulation tests profiles. This includes global assays such as prothrombin time (PT) or International Normalized Ratio (INR), activated Partial Thromboplastin Time (aPTT) and specialized assays dedicated to investigate well defined targets such as anti-Xa ot anti-IIa activities.
However, this approach may lack of accuracy as coagulation is a complex process including positive and negative feedback loops as displayed in figure 1. Thrombin plays a central role in the coagulation cascade, and although some drugs have specific targets different from thrombin, such as specific factor Xa inhibitors, they may induce an inhibition of the thrombin generation. This is for example the case for the indirect, *i.e.* antithrombin dependent, synthetic pentasaccharide fondaparinux (Arixtra®) and for the direct, *i.e.* antithrombin independent, DX-9065a facor Xa inhibitors [1, 2]. This property may be involved in the anticoagulant properties of anticoagulant drugs and the assay may be useful in the *in vitro* assessment of these compounds.
Different assays are available in order to assess the effect of anticoagulant drugs on thrombin generation, including a fluorogenic method allowing this determination in platelet rich plasma.
Results obtained in vitro at a early stage of pentasaccharide development demonstrated that this specific and pure anti-Xa compound is unable to suppress completely thrombin generation, but induces a maximal inhibition limited to 80% [3, 4, 5, 6]. Thrombinography or study of thrombin generation is the present reference assay for the evaluation of thrombin generation ; this method takes into account the kinetics and the amount of non neutralized thrombin formed all the time using a dedicated software.
Aventis has developed 12 heparinoid compounds, belonging to two different families, namely DIA2844 and WSD3093. These compounds differ from the length of the oligosaccharides sequence *i.e.* hexasaccharide, octasaccharide, decasaccharide, dodecasaccharide, < hexadecasaccharide and ≥ hexadecasaccharide.
It is admitted that all anticoagulant drugs may inhibit thrombin generation. The antithrombotic activity associated to an antithrombin dependent anti-Xa activity appears only for a number of saccharidic units with a molecular weight ≥ 5,400 D, i.e. 16 to 18 saccharidic units. Therefore, it is interesting to compare the thrombin inhibition induced by derivatives containing less than 16 saccharridic units to that induced by derivatives containing 16 or more derivatives. Results obtained for these two families of fractions, which mainly differ by the presence (for compounds containing 16 or more saccharidic units) or absence (for compounds containing less than 16 saccharidic units) of an antithrombin activity, although they exhibit quite a similar anti-Xa activity may be instructive.
On the other hand, hexa-, octa-, deca-, and dodecasaccharide fractions were studied separately and the interpretation of the results should take into account the anti-Xa and anti-IIa properties of these fractions.

The aim of this study is to compare the anticoagulant effect of these compounds evaluated as the inhibition of thrombin generation, as compared to enoxaparin, considered as the reference preparation.

Material and methods:

Reference material:

WSD3093 compounds:
- Hexasaccharide
- Octasaccharide
- Decasaccharide
- Dodecasaccharide
- < Hexadecasaccharide
- ≥ Hexadecasaccharide

and

DIA2844 compounds:
- Hexasaccharide
- Octasaccharide
- Decasaccharide
- Dodecasaccharide
- < Hexadecasaccharide
- ≥ Hexadecasaccharide

were provided by Aventis as powders.

Enoxaparin (batch # 314901) was also provided by Aventis as powder.

Thrombin generation assay:

Thrombin generation was assessed using the Thrombogram-Thrombinoscope assay developed by Hemker *et al.* [7, 8].

Principle of the assay:

The method consists of a study of the generation of thrombin, in real time, after recalcification of platelet rich plasma (PRP) in presence of tissue factor (TF) provided by a thromboplastin solution.

The thrombin amidolytic activity on a fluorogenic substrate is then measured.

The quantification of thrombin generated during a 45-minute period of observation is performed *via* the evaluation of the amidolytic activity by measurement of fluorescence, by comparison to a thrombin activity of a thrombin calibrator supplied by SYNAPSE.

The determination of thrombogram on PRP moves closer to conditions of the physiological haemostasis than the one performed on platelet poor plasma.

The rationale for the use of different dilutions of thromboplastin is based on the fact that:

(i) in *in vivo* conditions only trace amounts of tissue factor are present to trigger coagulation,

(ii) large amounts of thromboplastin may occult any anticoagulant activity leading to a poor sensitivity of the assay, and

(iii) in contrast low concentrations or total absence of thromboplastin may lead to a to highly sensitive system in which low concentrations of the anticoagulant drug may induce an *in vitro* "over-anticoagulation" and lead to ininterpretable results, the power of the anticoagulant drug playing a major role in this response.

Parameters of the thrombogram:

The software calculates the following parameters from thrombogram:

1. Lag-time :

It is the time required for a deviation superior to two standard-deviations of the fluorescent signal from the base line.
This parameter, informative for the phase of initiation of thrombin generation, is expressed in minutes.

2. Endogenous thrombin potential (ETP) :

It is the area under the curve. It represents the complete kinetics of thrombin generation in time.
This parameter allows to appreciate the quantity of thrombin generated and the time of its presence under active form in plasma.

3. Time to peak :

It is the time required for the generation of the maximal quantity of thrombin.
It is expressed in minutes.

4. Time to peak – lag time :

This parameter estimates the time to reach the peak once the reaction has started.

5. Start tail :

It is the time required, expressed in minutes, so that the thrombin concentration returns to zero.

Reagents for the thrombin generation assay:

i. Fluorogenic Substrate supplied by BACHEM , ref I-1140.0250.
ii. DMSO supplied by SIGMA, ref D-8418.
iii. HEPES supplied by SIGMA, ref H-7523.

iv. Calcium chloride Anhydrous supplied by SIGMA, ref C-4901.
v. Sodium chloride, 99,5% pure, supplied by MERCK, ref K-30005704.
vi. Hemoliance-Recombiplastin supplied by Instrumentation Laboratory, ref 49732750.
vii. 96 well plate (transparent polypropylene round bottom plate) supplied by Greiner, ref 650204.
viii. Thrombin Calibrator supplied by Synapse BV.
ix. Citrated Vacutainer supplied by BECTON DICKINSON, 129 mmol/L Citrated Natrium under 0,5 mL, ref 367704.

Reagents preparation:

1. Working buffer:

Hepes buffer (pH7.35,20mM Hepes), 140mM NaCl, BSA 5mg/mL.
For 1L, weigh 4.790 g d'Hepes, 8.223g NaCl and 5.208g BSA. Mix the different weighed in an 1 liter gauged phial and adjust with some distilled water.
This solution will be used for the preparation and the dilution of reagents.

Stability: 1 month, +4°C.

2. Fluo-buffer:

Hepes buffer (pH 7.35, 20mM Hepes), BSA 60mg/mL, sodium azide 0.02%.
For the preparation of Fluo-buffer it is necessary to add 6 g of BSA in 100 mL. Shake slightly during one hour. Then filter the preparation.
The preparation is then aliquoted and frozen at –20°C.

Stability : 1 month, –20°C.

3. $CaCl_2$, 1 M:

In a 200mL gauged phial, introduce 23.125 g of beforehand weighed CaCl2 and adjust with distilled water.

4. Washing buffer :

Mix 1 $CaCl_2$ 1M volume solution with 9 distilled water volumes.

5. Fluorogenic substrate:

Z-Gly-Gly-Arg-AMC I-1140 (Bachem).
In 3.76 mL of DMSO add 250mg of fluorogenic substrate.

Stability : 1 month, –20°C.

6. FluCa solution:

In 1750 μL of Fluo-Buffer, add 200μL $CaCl_2$ 1M. After 2-3 minutes, add 50 μL of fluorogenic substrate solution (100mM).

Stability: 1 month after preparation.

7. Thrombin standard by Synapse

Dissolve the flask contents in1 mL of distilled water.

Stability 1 month, –20°C.

8. Hemoliance-Recombiplastin

Dissolve the flask content in 5 mL of physiological water.

Stability : 15 days, +4°C.

All the samples will be tested with 3 following ones Hemoliance-Recombiplastin solutions:

. 1/40th Hemoliance-Recombiplastin diluted.
. 1/100th Hemoliance-Recombiplastin diluted.
. 1/200th Hemoliance-Recombiplastin diluted.

The indicated dilutions are the Hemoliance-Recombiplastin initial dilutions and do not take into account the final dilution (20 μL of Hemoliance-Recombiplastin solution + 80 μL of plasma). Therefore, final dilution are 5-fold higher i.e. 1/200th, 1/500th, and 1/1000th.

9. Heparinoïds concentration ranges in PRP:

9. a. Enoxaparin concentration range in PRP:

In a 25 mL gauged phial, introduce 10 mg of beforehand weighed enoxaparin and adjust **with distilled water** so as to obtain a 400 μg / mL enoxaparin stock solution in distilled water.
Store the enoxaparin solution at +4°C.

Prepare three enoxaparin working solutions as follows:

- 200 μg / mL enoxaparin solution: 1000 μL of the 400 μg / mL enoxaparin solution + 1000 μL of distilled water.
- 100 μg / mL enoxaparin solution: 500 μL of the 400 μg / mL enoxaparin solution + 1500 μL of distilled water.
- 50 μg / mL enoxaparin solution: 250 μL of the 400 μg / mL enoxaparin solution + 1750 μL of distilled water.

- 20 µg / mL enoxaparin solution: 100 µL of the 400 µg / mL enoxaparin solution + 1900 µL of distilled water.
- 10 µg / mL enoxaparin solution: 50 µL of the 400 µg / mL enoxaparin solution + 1950 µL of distilled water.
- 5 µg / mL enoxaparin solution: 25 µL of the 400 µg / mL enoxaparin solution + 1975 µL of distilled water.

Plasmas used will be added at the rate of 1 volume of working solution for 19 volumes of plasma to be tested (that is 40 µL of working solution + 760 µL of plasma) so as to obtain the Enoxaparine concentrations as following : 10 µg / mL , 5 µg / mL, 2.5 µg / mL, 1 µg / mL , 0.5 µg / mL and 0.25 µg / mL.

9. b. <u>Others heparinoïds concentration ranges in PRP:</u>

For each molecule, prepare the same range of concentrations in PRP.

10. PREPARATION OF PRP:

10.a. Drawing of blood.

Use a sodium citrated plasma, dripped in a Vacutainer tube (nine volumes of blood to one volume of sodium citrate solution). Be sure that the sodium citrate is at least at 15°C.
1 to 2 mL of blood is needed for each curve that you want to measure.

10.b. Centrifugation and platelet count.

Preparation of PPP.

Centrifuge at 2000 g at 15°C immediately after the blood collection. It is advisable to centrifuge twice to remove all platelets.

Preparation of PRP.

Tubes are centrifuged for 10 min at room temperature, at 130 g, at 15 °C.
The PRP is pipetted off after centrifugation and collected.
Platelet count is measured on the BAYER ADVIA 120 counter.
Then, tubes are centrifuged again for 10 min at 2000 g at room temperature.
The PPP is pipetted off and used to **adjust the PRP to 150,000 platelets /µL.**

Example: when the platelet count is 460,000, take 150 µL of PRP and add 310 µL of PPP or any multiplication of these numbers.

Assay procedure:

1. PRP pool preparation :

PRP pool will be prepared from blood obtained from healthy volunteers using sodium citrate as an anticoagulant.

Two citrated Vacutainer tubes (ref BD 367704) will be taken from 20 subjects so as to prepare 80 mL of PRP.

For PRP pool, a test of thrombin generation will be performed in the presence of the Hemoliance-Recombiplastin solutions described above.

2. Calibration :

Well calibrator (Yellow colour):	20 µL of Thrombin calibrator 80 µL of PRP

3. PRP thrombogram values :

Associated samples well (red colour): 20 μL of Hemoliance-Recombiplastin solution various dilutions SRC (1/40, 1/100, 1/200) and 80 μL of PRP

Two determinations will be made for each Hemoliance-Recombiplastin dilution.

The assay will then be run according to the manufacturer's procedure.

Results:

Influence of the thromboplastin dilution:

The more the thromboplastin is diluted, the more sensitive is the assay for the measurement of the inhibitory activity to the different heparinoïd preparations (Table I and figure 2).
Uninterpretable results were observed for the highest dilution (1/200th) of thromboplastin for the highest concentrations of heparinoïd compounds.
On the other hand, the difference observed between the compounds was enhanced by a 1/100th dilution of the thromboplastin as compared to the 1/40th dilution, although no detectable signal was observed for the highest concentration (i.e. 10 μg/mL) of DIA ≥ hexadecasaccharide (total inhibition of thrombin generation).
Therefore we selected the 1/100th thromboplastin dilution.

Comparative effect of the heparinoïd compounds on thrombin generation (Table I) :

Lag-time:

Only a minimal effect on lag time was observed with the different heparinoïd compounds at the concentration range tested, except for the WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide compounds, which induced a prolongation of the lag time (figure 3).

ETP:

Oligosaccharide (hexa-, octa-, deca-, and dodecasaccharide) and fractions < 16 hexadecasaccharide have a limited effect, inferior to the one of enoxaparin.
WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide induced a higher inhibition of ETP than enoxaparin. The effect was more pronounced with DIA ≥ hexadecasaccharide than with WSD ≥ hexadecasaccharide.
All the other compounds induced a more limited inihibition of ETP than enoxaparin.
Results for ETP are displayed in figure 4. Table II summarizes results for 1/100th diluted Recombiplaston.

Peak:

WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide induced a more important reduction of the peak than enoxaparin. The effect was more pronounced with DIA ≥ hexadecasaccharide than with WSD ≥ hexadecasaccharide.
All the other compounds induced a more limited inhibition of ETP than enoxaparin (figure 5).

Time to peak:

WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide induced a more pronounced delay of the time to peak than the other compounds. The response of the WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide were however quite similar (figure 6).

Time to peak – lag time:

WSD ≥ hexadecasaccharide induced a prolongation of the time to peak – lag time parameter as compared to the other compounds (figure 7).

Start-tail:

Results were very variable from one compound to another. However, WSD ≥ hexadecasaccharide seemed to prolong more the start-tail than the other compounds (figure 8).

Preliminary conclusions (Tables I and II):

The oligosaccharides (hexa-, octa-, deca- and dodecasaccharide) and the < hexadecasaccharide fractions induce a limited inhibition only found for the highest concentrations of thrombin generation as compared to enoxaparin. Furthermore, no difference was observed between the preparation families WSD and DIA.

However, interestingly, two compounds, namely WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide exhibited a more important response than enoxaparin.
The two most relevant parameters are ETP and peak. For these parameters, the effect of DIA ≥ hexadecasaccharide could be more important than this of WSD ≥ hexadecasaccharide and requires further investigation.

Therefore complementary experiments were decided in order to:

(i) confirm the finding obtained in the preliminary run for WSD ≥ hexadecasaccharide, DIA ≥ hexadecasaccharide, and enoxaparin;
(ii) implement additional concentrations of the compounds in the range of interest according to the preliminary results, using the 1/100th thromboplastin dilution;
(iii) assess the intra- and inter-individual variation of the response.

Complementary experiments:

Runs were performed using the following WSD ≥ hexadecasaccharide, DIA ≥ hexadecasaccharide and enoxaparin concentration range: 10 μg / mL , 9 μg / mL ,

8 μg / mL , 6.25 μg / mL, 5 μg / mL, 4 μg / mL, 2.5 μg / mL, 1.6 μg / mL, 1 μg / mL and 0.5 μg / mL, and 0 μg / mL.

A run was performed in quadriplicate using the same donor as in the preliminary experiment (table III).

Another run was performed in triplicate using another donor (table IIV).

Lag time:

No difference was observed between WSD ≥ hexadecasaccharide, DIA ≥ hexadecasaccharide and enoxaparin for the lag-time in the two subjects (figures 9 and 10). The lag-phase was prolonged in a dose-dependent manner for concentrations equal or higher than 2.5 μg/mL. The lag-phase was prolonged by 31% and 33% for a 5 μg/mL WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide respectively in one subject and 38% and 43% for the other.

ETP:

The results confirmed that WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide had a more pronounced effect than enoxaparin. DIA ≥ hexadecasaccharide seemed to have a higher effect (estimated around 10%) than WSD ≥ hexadecasaccharide, at least for concentrations lower than 8 - 10 μg/mL, the difference between the two preparations being less important for that high concentration, probably due to the limitation of the methodology (figures 11 and 12). ETP was decreased in a dose-dependent manner for concentrations equal or higher than 2.5 μg/mL. ETP was decreased by 58% and 68% for a 5 μg/mL WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide respectively in one subject and 56% and 66% for the other. A 93% and 92% ETP inhibition was obtained for a 10 μg/mL WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide respectively in one subject and 83% and 91% in the other.

Peak:

Only a minimal effect was observed for low concentrations of WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide (< 2 – 3 μg/mL) and the results are difficult to interpret.

The effect of WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide was more pronounced than for enoxaparin for concentrations higher than 4 μg/mL.

DIA ≥ hexadecasaccharide exhibited a slightly higher effect than WSD ≥ hexadecasaccharide (figures 13 and 14).

The peak was decreased in a dose-dependent manner for concentrations equal or higher than 2.5 μg/mL. The peak was decreased by 73% and 79% for a 5 μg/mL WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide respectively in one subject and 63% and 76% for the other. A 97% and 96% peak inhibition was obtained for a 10 μg/mL

WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide respectively in one subject and 92% and 96% in the other.

Time to peak:

No difference was observed between the three compounds WSD ≥ hexadecasaccharide, DIA ≥ hexadecasaccharide and enoxaparin (figures 15 and 16).

Time to peak was prolonged in a dose-dependent manner for concentrations equal or higher than 2.5 μg/mL. Time to peak was prolonged by 66% and 42% for a 5 μg/mL WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide respectively in one subject and 51% and 76% for the other. A 113% and 176% time to peak prolongation was obtained for a 10 μg/mL WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide respectively in one subject and 133% and 151% in the other.

Time to peak – lag time:

No difference was observed between WSD ≥ hexadecasaccharide, DIA ≥ hexadecasaccharide and enoxaparin (figures 17 and 18).

Time to peak – lag time was prolonged in a dose-dependent manner for concentrations equal or higher than 2.5 μg/mL. Time to peak – lag time was prolonged by 88% and 47% for a 5 μg/mL WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide respectively in one subject and 60% and 100% for the other. A 146% and 230% time to peak – lag time prolongation was obtained for a 10 μg/mL WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide respectively in one subject and 157% and 160% in the other.

Start tail:

No difference was observed between WSD ≥ hexadecasaccharide, DIA ≥ hexadecasaccharide and enoxaparin (figures 19 and 20). Only a minimal effect was observed for the lowest concentrations (less than 5 μg/mL). For higher concentrations, a dose-effect prolongation of the start tail was observed. Start tail was prolonged by 34% and 44% for a 5 μg/mL WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide respectively in one subject and 3% and 13% for the other. A 52% and 60% start tail prolongation was obtained for a 10 μg/mL WSD ≥ hexadecasaccharide and DIA ≥ hexadecasaccharide respectively in one subject and 66% and 50% in the other.

Overall conclusion:

Thrombinography is considered as a reference method to evaluate anticoagulant drugs. The concept of thrombinography involves a global approach of the mechanisms of anticoagulation, which is not limited to supposed well defined targets such as factor Xa or thrombin. Moreover it is an appropriate test for the evaluation of multi-targeted drugs.
Heparinoid fractions may include both anti-Xa and anti-IIa activities, the relative potency of which is closely related to the number of saccharidic units i.e. to the molecular weight of the preparation. Therefore, thrombinography allows the comparison of the thrombin generation inhibition potency of different preparations which may have a similar anti-Xa activity, but which differ from a chemical point of view.
Aventis has developed two families of compounds (WSD 3093 and DIA2844) which both include different fractions, namely hexa-, octa-, deca-, < hexadecasaccharide, and ≥ hexadecasaccharide. The aim of this study was to compare the ability of these different preparations to inhibit thrombin generation.

The assay was run in fresh platelet rich plasma which is close to physiological coagulation conditions.
Different dilutions of thromboplastin were used in the preliminary experiments in order to find the most appropriate dilution of thromboplastin which induces a sensitive and interpretable response of the assay for the different compounds.

Our results confirm that enoxaparin inhibits thrombin generation and a clear dose effect relationship was observed.

Oligosaccharides and fractions < hexadecasaccharide exhibit a limited inhibition of thrombin generation as compared to enoxaparin. No difference was observed between the two families of compounds WSD and DIA for these preparations in the assay used in this study.

Interestingly, there is a difference in the response of thrombin generation (extrinsic pathway) for ≥ hexadecasaccharide and < hexadecasaccharide compounds, ≥ hexadecasaccharide compounds being more active than < hexadecasaccharide preparations. However, the effect is clearly highlighted for concentrations around 2.5 – 5 μg/mL.
≥ hexadecasaccharide fractions are more potent in the thrombin generation inhibition than enoxaparin. This might be correlated to the fact that the assay is not only partially sensitive to the anti-Xa activity, but also very sensitive to the anti-IIa activity. The importance of this characteristic of the assay in its clinical relevance requires further investigation.
The effect is particurlaly marked for ETP which, as the area under the curve, includes the amount of thrombin formed and the time to form this thrombin. ETP is curretly considered as the most robust parameter of the thrombogram. However, a clear effect is also demonstrated for the lag time, the peak, the time to peak and time to peak – lag time. The effect is less clear for the start tail which should be considered as an exploratory end-point and could be more appropriate for direct thrombin inhibitors.

These results are interesting and underline that in this test, for these compounds, the inhibition of thrombin generation is more potent than the inhibition of factor Xa, which does not mean however that it is of clinical relevance.

Finally, the DIA ≥ hexadecasaccharide fraction induces a more potent inhibition of thrombin generation than the WSD ≥ hexadecasaccharide fraction. The difference observed between these two fractions might be related to the chemical structure of these fractions. These results support that according to their chemical structure, two compounds of comparable molecular weight may exhibit different activities. This difference may be of interest when trying to identify differences between different low molecular weight heparins. However, since the difference between the responses obtained for the two families of compounds remain of low intensity, further investigation seems desirable.

References:

[1] Petitou M, Duchaussoy P, Herbert JM, Dur G, El Hajii M, Branellec JF, Donat F, Necciari J, Cariou R, Bouthier J, Garrigou E. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Hemost 2002; 28: 393-402.

[2] Nagashima H. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and argatroban. I. Effects on thrombin generation. J Biol Chem 2002; 277: 50439-50444.

[3] Walenga JM, Bara L, Petitou M, Samama M, Fareed J, Choay J. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Thromb Res 1988; 51: 23-33.

[4] Thomas DP, Merton RE, Gray E, Barrowcliffe TW. The relative antithrombotic effectivness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model. Thromb Haemost 1989; 61: 204-7.

[5] Béguin S, Choay J, Hemker HC. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost 1989; 61: 397-401.

[6] Lormeau JC, Herault JP. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic ATIII-binding pentasaccharide. Thromb Haemost 1993; 69: 152-6.

[7] Hemker HC, Giesen P, Al Dieri R, Regnault V, De Smedt E, Wavenvoord R, Lecompte T. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-53.

[8] Hemker HC, Giesen P, Al Dieri R, Regnault V, De Smedt E, Wavenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.



Figure 1 : Coagulation process and antithrombotic drugs
A vascular lesion or the atherosclerotic plaque fracture induces the release of tissue factor, which binds to factor VII activated in factor VIIa. This complex induces the activation of factor X in factor Xa, which, in combination with factor Va, and phospholipids forms the prothrombinase complex. This prothrombinase complex activates prothrombin into thrombin. Thrombin plays a multifactorial and central role in the coagulation process by (i) activating platelets, (ii) transforming fibrinogen into fibrin and by activating factor V and factor VIII in factors Va and VIIIa respectively. In addition, the tissue factor – factor VIIa complex activates factor IX into factor IXa, which, in combination with factor VIIIa and phospholipids forms the "intrinsic tenase" that activates factor X into factor Xa.
The development and the comprehension of the mechanism of action of new antithrombotic drugs is partly based on this concept of the coagulation process.

APPENDICES

	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail
	1,5	1637	312,5	3,5	2	16	2,25	1593	204,07	6	3,75	21	3,25	1582	159,26	8,5	5,25	24
	1,5	1661	309,53	3,75	2,25	16	2,25	1621	209,86	6	3,75	21	3,25	1592	160,21	8,5	5,25	23
	1,5	1636	314,36	3,5	2	16	2,25	1614	210,32	5,75	3,5	20	3,25	1593	175,57	8	4,75	22
	1,5	1535	315,7	3,5	2	16	2,25	1517	211,37	5,5	3,25	20	3,25	1523	158,84	8,25	5	24
Mean	1,50	1617,25	312,77	3,56	2,06	16,00	2,25	1586,25	208,91	5,81	3,56	20,50	3,25	1572,50	162,97	8,31	5,06	23,25
SD	0,00	56,04	3,12	0,13	0,13	0,00	0,00	47,68	3,28	0,24	0,24	0,58	0,00	33,37	8,52	0,24	0,24	0,96
CV %	0	3	1	4	6	0	0	3	2	4	7	3	0	2	5	3	5	4

Tested molecule	PRP + HEPARINOID 0,25 µg / mL																	
	With Hemoliance Recombiplastin 1/40 diluted						With Hemoliance Recombiplastin 1/100 diluted						With Hemoliance Recombiplastin 1/200 diluted					
	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail
Enoxaparine	1,64	1368	279,82	3,46	1,82	16	2,16	1462	211,85	5,01	2,95	20	2,94	1414	176,13	6,57	3,63	21
Enoxaparine	1,64	1400	278,78	3,46	1,82	16	2,16	1419	214,29	4,75	2,59	19	2,68	1433	190,42	6,31	3,63	21
Mean	1,64	1383,00	279,30	3,46	1,82	16,00	2,16	1440,50	213,07	4,88	2,72	19,50	2,81	1423,50	178,28	6,44	3,63	21,00
SD	0,00	24,04	0,74	0,00	0,00	0,00	0,00	30,41	1,73	0,18	0,18	0,71	0,18	13,44	3,03	0,18	0,00	0,00
CV %	0	2	0	0	0	0	0	2	1	4	7	4	7	1	2	3	0	0
n versus not heparinoid added PRP %	9	-14	-11	-3	-78	0	-4	-9	2	-16	-67	-5	-14	-9	9	-23	-56	-10
WSD3093-Hexasaccharides	1,39	1456	294,34	3,46	2,07	15	2,16	1505	239,36	4,49	2,33	16	2,94	1386	172,26	6,57	3,63	19
WSD3093-Hexasaccharides	1,64	1487	289,73	3,72	2,08	14	2,16	1541	236,98	4,75	2,59	17	2,68	1391	169,07	6,31	3,63	21
Mean	1,52	1471,50	292,04	3,59	2,08	14,50	2,16	1523,00	238,18	4,62	2,46	16,50	2,81	1388,50	170,66	6,44	3,63	20,00
SD	0,18	21,92	3,26	0,18	0,01	0,71	0,00	25,46	1,68	0,18	0,18	0,71	0,18	3,54	2,25	0,18	0,00	1,41
CV %	12	1	1	5	0	5	0	2	1	4	7	4	7	0	1	3	0	7
n versus not heparinoid added PRP %	1	-9	-7	1	-75	-9	-4	-4	14	-21	-70	-20	-14	-12	5	-23	-56	-14
on versus Enoxaparine added PRP %	-8	6	5	4	-68	-9	0	6	12	-5	-62	-15	0	-2	-4	0	-44	-5
WSD3093-Octasaccharides	1,64	1580	290,62	3,71	2,07	19	2,16	1605	241,69	5	2,84	20	2,94	1598	205,57	6,81	3,87	19
WSD3093-Octasaccharides	1,64	1560	295,71	3,71	2,07	17	2,16	1535	238,43	5	2,84	18	2,94	1576	212,26	6,3	3,36	21
Mean	1,64	1570,00	293,17	3,71	2,07	18,00	2,16	1570,00	240,06	5,00	2,84	19,00	2,94	1587,00	208,92	6,56	3,62	20,00
SD	0,00	14,14	3,60	0,00	0,00	1,41	0,00	49,50	2,31	0,00	0,00	1,41	0,00	15,56	4,73	0,36	0,36	1,41
CV %	0	1	1	0	0	8	0	3	1	0	0	7	0	1	2	6	10	7
n versus not heparinoid added PRP %	9	-3	-6	4	-75	13	-4	-1	15	-14	-66	-7	-10	1	28	-21	-57	-14
on versus Enoxaparine added PRP %	0	14	5	7	-68	13	0	9	13	2	-56	-3	5	11	17	2	-44	-5
WSD3093-Decasaccharides	1,64	1557	304,33	3,45	1,81	16	2,16	1504	245,06	4,75	2,59	19	2,94	1452	199,68	6,3	3,36	20
WSD3093-Decasaccharides	1,64	1592	287,66	3,71	2,07	23	2,16	1475	228,1	5	2,84	18	2,94	1552	208,83	6,04	3,1	24
Mean	1,64	1574,50	296,00	3,58	1,94	19,50	2,16	1489,50	236,58	4,88	2,72	19,00	2,94	1502,00	204,26	6,17	3,23	22,00
SD	0,00	24,75	11,79	0,18	0,18	4,95	0,00	20,51	11,99	0,18	0,18	0,00	0,00	70,71	6,47	0,18	0,18	2,83
CV %	0	2	4	5	9	25	0	1	5	4	7	0	0	5	3	3	6	13
n versus not heparinoid added PRP %	9	-3	-5	0	-77	22	-4	-6	13	-16	-67	-7	-10	-4	25	-26	-61	-5
on versus Enoxaparine added PRP %	0	14	6	3	-70	22	0	3	11	0	-58	-3	5	6	15	-4	-50	5
WSD3093-Dodecasaccharides	1,9	1561	248,71	4,24	2,34	18	2,42	1605	183,22	6,06	3,64	23	3,46	1429	116,46	9,95	6,49	27
WSD3093-Dodecasaccharides	1,8	1553	263,38	4,24	2,34	17	2,68	1495	155,14	6,68	3,9	23	3,46	1490	133,17	9,17	5,71	25
Mean	1,90	1557,00	256,05	4,24	2,34	17,50	2,55	1550,00	169,18	6,32	3,77	23,00	3,46	1459,00	124,82	9,56	6,10	26,00
SD	0,00	5,66	10,38	0,00	0,00	0,71	0,18	77,78	19,86	0,37	0,18	0,00	0,00	43,84	11,82	0,55	0,55	1,41
CV %	0	0	4	0	0	4	7	5	12	6	5	0	0	3	9	6	9	5
n versus not heparinoid added PRP %	27	-4	-18	19	-72	9	13	-2	-19	9	-55	12	6	-7	-23	15	-27	12
on versus Enoxaparine added PRP %	16	13	-8	23	-64	9	18	8	-21	30	-41	18	23	2	-30	48	-5	24
WSD3093-<Hexadecasaccharides	1,9	1435	237,81	4,24	2,34	19	2,68	1492	164,65	6,06	3,38	28	3,46	1454	122,04	8,4	4,94	28
WSD3093-<Hexadecasaccharides	1,9	1523	245,47	4,24	2,34	19	2,68	1428	152,95	6,32	3,64	25	3,46	1337	113,02	9,17	5,71	26
Mean	1,90	1479,00	241,64	4,24	2,34	19,00	2,68	1460,00	158,80	6,19	3,51	26,50	3,46	1395,50	117,53	8,79	5,33	27,00
SD	0,00	62,23	5,56	0,00	0,00	0,00	0,00	45,25	8,27	0,18	0,18	2,12	0,00	82,73	6,38	0,54	0,54	1,41
CV %	0	4	2	0	0	0	0	3	5	3	5	8	0	6	5	6	10	5
n versus not heparinoid added PRP %	27	-9	-23	19	-72	19	19	-8	-24	6	-58	29	6	-11	-28	6	-36	16
on versus Enoxaparine added PRP %	16	7	-14	23	-64	19	24	1	-25	27	-45	36	23	-2	-34	36	-17	29
>=Hexadecasaccharides	1,25	1464	314,07	3,25	2	13	2	1716	245,1	4,75	2,75	30	2,91	1404	153,43	8,08	5,17	17
>=Hexadecasaccharides	1,5	1774	312,81	3,5	2	24	2	1801	246,64	4,75	2,75	27	2,75	1655	206,05	6,5	3,75	28
Mean	1,38	1619,00	313,49	3,38	2,00	18,50	2,00	1758,50	245,87	4,75	2,75	28,50	2,83	1529,50	179,74	7,29	4,46	22,50
SD	0,18	219,20	0,82	0,18	0,00	7,78	0,00	60,10	1,09	0,00	0,00	2,12	0,11	177,48	37,21	1,12	1,00	7,78
CV %	13	14	0	5	0	42	0	3	0	0	0	7	4	12	21	15	23	35
n versus not heparinoid added PRP %	-8	0	0	-5	-76	16	-11	11	18	-18	-67	39	-13	-3	10	-12	-46	-3
on versus Enoxaparine added PRP %	-16	17	12	-2	-69	16	-7	22	15	-3	-57	46	1	7	1	13	-31	7
DIA2844-Hexasaccharides	1,88	1691	263,44	4,46	2,58	19	2,65	1662	185,77	6,27	3,62	25	3,43	1564	134,42	8,6	5,17	26
DIA2844-Hexasaccharides	1,88	1728	278,89	4,2	2,32	18	2,65	1671	185,73	6,27	3,62	22	3,43	1659	143,19	8,85	5,42	27
Mean	1,88	1709,50	271,22	4,33	2,45	18,50	2,65	1666,50	185,75	6,27	3,62	23,50	3,43	1611,50	138,81	8,73	5,30	26,50
SD	0,00	26,16	11,00	0,18	0,18	0,71	0,00	6,36	0,03	0,00	0,00	2,12	0,00	67,18	6,20	0,18	0,18	0,71
CV %	0	2	4	4	8	4	0	0	0	0	0	9	0	4	4	2	3	3
n versus not heparinoid added PRP %	25	6	-13	22	-71	16	18	5	-11	8	-56	15	6	2	-15	5	-36	14
on versus Enoxaparine added PRP %	15	24	-3	25	-62	16	23	16	-13	28	-44	21	22	13	-22	35	-18	26
DIA2844-Octasaccharides	1,9	1771	288,43	4,23	2,33	20	2,68	1727	215,7	5,78	3,1	22	3,71	1699	161,4	8,37	4,68	26
DIA2844-Octasaccharides	1,9	1691	301,17	3,97	2,07	16	2,94	1718	208,82	6,04	3,1	23	3,45	1705	179,31	7,59	4,14	26
Mean	1,90	1731,00	294,80	4,10	2,20	18,00	2,81	1723,00	212,31	5,91	3,10	22,50	3,58	1702,00	170,36	7,98	4,40	26,00
SD	0,00	56,57	9,01	0,18	0,18	2,83	0,18	5,66	4,79	0,18	0,00	0,71	0,18	4,24	12,68	0,55	0,37	0,00
CV %	0	3	3	4	8	16	7	0	2	3	0	3	5	0	7	7	8	0
n versus not heparinoid added PRP %	27	7	-6	15	-74	13	25	9	2	2	-63	10	10	8	5	-4	-47	12
on versus Enoxaparine added PRP %	16	25	6	18	-66	13	30	20	0	21	-52	15	27	20	-4	24	-32	24
DIA2844-Decasaccharides	1,9	1634	281,96	4,23	2,33	19	2,68	1676	203,58	5,78	3,1	26	3,45	1739	165,44	7,59	4,14	27
DIA2844-Decasaccharides	1,9	1610	285,38	3,97	2,07	17	2,68	1696	196,83	6,04	3,36	30	3,45	1581	167,98	7,85	4,4	25
Mean	1,90	1622,00	283,67	4,10	2,20	18,00	2,68	1681,00	200,21	5,91	3,23	28,00	3,45	1660,00	166,72	7,72	4,27	26,00
SD	0,00	16,97	2,42	0,18	0,18	1,41	0,00	7,07	4,77	0,18	0,18	2,83	0,00	111,72	1,90	0,18	0,18	1,41
CV %	0	1	1	4	8	8	0	0	2	3	6	10	0	7	1	2	4	5
n versus not heparinoid added PRP %	27	0	-9	15	-74	13	19	6	-4	2	-61	37	6	6	2	-7	-49	12
on versus Enoxaparine added PRP %	16	17	2	18	-66	13	24	17	-6	21	-50	44	23	17	-6	20	-34	24
DIA2844-Dodecasaccharides	1,87	1784	280,85	4,2	2,33	24	2,65	1608	189,9	6,27	3,62	20	3,42	1672	159,88	8,08	4,66	25
DIA2844-Dodecasaccharides	1,87	1701	285,69	4,2	2,33	19	2,91	1574	183,06	6,27	3,36	21	3,42	1707	162,63	7,82	4,4	27
Mean	1,87	1732,50	283,12	4,20	2,33	21,50	2,78	1591,00	186,48	6,27	3,49	20,50	3,42	1689,50	161,26	7,95	4,53	26,00
SD	0,00	44,55	3,49	0,00	0,00	3,54	0,18	24,04	4,84	0,00	0,18	0,71	0,00	24,75	1,94	0,18	0,18	1,41
CV %	0	3	1	0	0	16	7	2	3	0	5	3	0	1	1	2	4	5
n versus not heparinoid added PRP %	25	7	-9	18	-72	34	24	0	-11	8	-58	0	5	7	-1	-4	-46	12
on versus Enoxaparine added PRP %	14	25	1	21	-64	34	29	10	-12	28	-46	5	22	19	-10	23	-30	24
DIA2844-<Hexadecasaccharides	1,87	1758	281,51	4,46	2,58	19	2,65	1684	200,17	6,27	3,62	24	3,42	1684	168,45	7,82	4,4	27
DIA2844-<Hexadecasaccharides	1,87	2055	337,46	4,2	2,33	15	2,65	1686	213,1	6,01	3,36	20	3,68	1679	159,49	8,08	4,4	25
Mean	1,87	1905,50	309,49	4,33	2,46	17,00	2,65	1685,00	206,64	6,14	3,49	22,00	3,55	1681,50	162,97	7,95	4,40	26,00
SD	0,00	211,42	39,56	0,18	0,18	2,83	0,00	1,41	9,14	0,18	0,18	2,83	0,18	3,54	4,92	0,18	0,00	1,41
CV %	0	11	13	4	7	17	0	0	4	3	5	13	5	0	3	2	0	5
n versus not heparinoid added PRP %	25	18	-1	22	-70	6	18	6	-1	6	-58	7	0	7	0	-4	-47	12
on versus Enoxaparine added PRP %	14	38	11	25	-62	6	23	17	-3	26	-46	13	26	18	-9	23	-32	24
DIA2844->=Hexadecasaccharides	1,75	1467	272,56	4	2,25	16	2,5	1443	200,61	5,25	2,75	22	3,25	1495	148,52	7,5	4,25	26
DIA2844->=Hexadecasaccharides	1,75	1530	275,86	3,75	2	21	2,5	1413	193,42	5,25	2,75	21	3,25	1546	154,69	7,25	4	26
Mean	1,75	1498,50	274,21	3,88	2,13	18,50	2,50	1428,00	197,02	5,25	2,75	21,50	3,25	1520,50	151,61	7,38	4,13	26,00
SD	0,00	44,55	2,33	0,18	0,18	3,54	0,00	21,21	5,08	0,00	0,00	0,71	0,00	36,06	4,38	0,18	0,18	0,00
CV %	0	3	1	5	8	19	0	1	3	0	0	3	0	2	3	2	4	0
n versus not heparinoid added PRP %	17	-7	-12	9	-74	16	11	-10	-6	-10	-67	5	0	-3	-7	-11	-50	12
on versus Enoxaparine added PRP %	7	8	-2	12	-67	16	16	-1	-8	8	-57	10	16	7	-15	15	-35	24

	Lagtime	ETP	Peak	tfPeak	tfP - LT	startTail	Lagtime	ETP	Peak	tfPeak	tfP - LT	startTail	Lagtime	ETP	Peak	tfPeak	tfP - LT	startTail
	1,5	1637	312,5	3,5	2	16	2,25	1593	204,07	6	3,75	21	3,25	1582	159,26	8,5	5,25	24
	1,5	1661	308,53	3,75	2,25	16	2,25	1621	209,86	6	3,75	21	3,25	1592	160,21	8,5	5,25	23
	1,5	1658	314,36	3,5	2	16	2,25	1614	210,32	5,75	3,5	20	3,25	1593	175,57	9	4,75	22
	1,5	1535	315,7	3,5	2	16	2,25	1517	211,37	5,5	3,25	20	3,25	1523	156,84	8,25	5	24
Mean	1,50	1617,25	312,77	3,56	2,06	16,00	2,25	1588,25	208,91	5,81	3,56	20,50	3,25	1572,50	162,97	8,31	5,06	23,25
SD	0,00	56,04	3,12	0,13	0,13	0,00	0,00	47,69	3,28	0,24	0,24	0,58	0,00	33,37	8,52	0,24	0,24	0,96
CV %	0	3	1	4	6	0	0	3	2	4	7	3	0	2	5	3	5	4

Tested molecule	PRP + HEPARINOID 0,5 µg / mL																	
	With Hemoliance Recombiplastin 1/40 diluted						With Hemoliance Recombiplastin 1/100 diluted						With Hemoliance Recombiplastin 1/200 diluted					
	Lagtime	ETP	Peak	tfPeak	tfP - LT	startTail	Lagtime	ETP	Peak	tfPeak	tfP - LT	startTail	Lagtime	ETP	Peak	tfPeak	tfP - LT	startTail
Enoxaparine	1,39	1414	278,66	3,46	2,07	17	1,9	1410	216,09	4,75	2,85	16	2,68	1392	177,08	6,05	3,37	20
Enoxaparine	1,39	1390	275,92	3,46	2,07	17	1,9	1436	210,2	4,75	2,85	19	2,68	1419	171,7	6,31	3,63	23
Mean	1,39	1402,00	277,24	3,46	2,07	17,00	1,90	1423,00	213,15	4,75	2,85	17,50	2,68	1405,50	174,39	6,18	3,50	21,50
SD	0,00	16,97	2,01	0,00	0,00	0,00	0,00	18,38	4,16	0,00	0,00	2,12	0,00	19,09	3,96	0,18	0,18	2,12
CV %	0	1	1	0	0	0	0	1	2	0	0	12	0	1	2	3	5	10
Variation versus not heparinoid added PRP %	-7	-13	-11	-3	-75	6	-16	-10	2	-18	-66	-15	-18	-11	7	-26	-58	-8
WSD3093-Hexasaccharides	1,39	1372	276,2	3,46	2,07	14	2,16	1359	202,31	4,75	2,59	17	2,68	1534	188,38	6,31	3,63	21
WSD3093-Hexasaccharides	1,64	1348	272,13	3,46	1,82	15	1,9	1372	212,75	4,75	2,85	15	1,25	1656	263,64	5,25	4	16
Mean	1,52	1360,00	274,17	3,46	1,95	14,50	2,03	1365,50	207,53	4,75	2,72	16,00	1,97	1595,00	226,01	5,78	3,82	18,50
SD	0,18	16,97	2,88	0,00	0,18	0,71	0,18	9,19	7,38	0,00	0,18	1,41	1,01	88,27	53,22	0,75	0,26	3,54
CV %	12	1	1	0	9	5	9	1	4	0	7	9	51	5	24	13	7	19
Variation versus not heparinoid added PRP %	1	-16	-12	-3	-77	-9	-10	-14	-1	-18	-67	-22	-40	1	39	-30	-54	-20
Variation versus Enoxaparine added PRP %	9	-3	-1	0	-69	-15	7	-4	-3	0	-56	-9	-27	13	30	-6	-38	-14
WSD3093-Octasaccharides	1,64	1633	307,46	3,71	2,07	14	2,16	1662	237	5,26	3,1	19	2,94	1653	219,5	6,91	3,87	19
WSD3093-Octasaccharides	1,64	1633	310,04	3,45	1,81	16	2,42	1626	236,68	5,26	2,84	18	2,68	1620	214,07	6,3	3,62	20
Mean	1,64	1633,00	308,76	3,58	1,94	15,00	2,29	1644,00	236,84	5,26	2,97	18,50	2,81	1636,50	216,79	6,56	3,75	19,50
SD	0,00	0,00	1,81	0,18	0,18	1,41	0,18	25,46	0,23	0,00	0,18	0,71	0,18	23,33	3,84	0,36	0,18	0,71
CV %	0	0	1	5	9	9	8	2	0	0	6	4	7	1	2	6	5	4
Variation versus not heparinoid added PRP %	9	1	-1	0	-77	-6	2	4	13	-10	-64	-10	-14	4	33	-21	-55	-16
Variation versus Enoxaparine added PRP %	18	16	11	3	-69	-12	21	16	11	11	-52	6	5	16	24	6	-39	-9
WSD3093-Decasaccharides	1,64	1635	286,39	3,71	2,07	21	2,16	1511	238,08	4,75	2,59	17	2,68	1518	206,4	6,3	3,62	21
WSD3093-Decasaccharides	1,64	1558	289,01	3,71	2,07	21	2,16	1506	237,55	5	2,64	21	2,94	1478	204,91	6,3	3,38	20
Mean	1,64	1596,50	287,70	3,71	2,07	21,00	2,16	1508,50	237,82	4,88	2,72	19,00	2,81	1498,00	205,65	6,30	3,49	20,50
SD	0,00	54,45	1,85	0,00	0,00	0,00	0,00	3,54	0,37	0,18	0,18	2,83	0,18	28,28	1,05	0,00	0,18	0,71
CV %	0	3	1	0	0	0	0	0	0	4	7	15	7	2	1	0	5	3
Variation versus not heparinoid added PRP %	9	-1	-8	4	-75	31	-4	-5	14	-16	-67	-7	-14	-5	26	-24	-58	-12
Variation versus Enoxaparine added PRP %	18	14	4	7	-67	24	14	6	12	3	-56	9	5	7	18	2	-44	-5
WSD3093-Dodecasaccharides	1,9	1578	258,32	4,24	2,34	19	2,68	1531	155,84	6,32	3,64	21	3,2	1577	147,8	7,88	4,68	28
WSD3093-Dodecasaccharides	1,64	1601	263,98	3,88	2,34	20	2,42	1625	170,64	6,06	3,64	24	3,46	1428	118,07	9,43	5,97	26
Mean	1,77	1589,50	261,15	4,11	2,34	19,50	2,55	1578,00	163,24	6,19	3,64	22,50	3,33	1502,50	132,94	8,66	5,33	27,00
SD	0,18	16,26	4,00	0,18	0,00	0,71	0,18	66,47	10,47	0,18	0,00	2,12	0,18	105,96	21,02	1,10	0,91	1,41
CV %	10	1	2	4	0	4	7	4	8	3	0	9	6	7	16	13	17	5
Variation versus not heparinoid added PRP %	18	-2	-17	15	-72	22	13	-1	-22	6	-56	10	2	-4	-18	4	-36	16
Variation versus Enoxaparine added PRP %	27	13	-6	19	-62	15	34	11	-23	30	-41	29	24	7	-24	40	-14	26
WSD3093-Hexadecasaccharides	1,64	1578	245,72	4,24	2,6	20	2,68	1559	158,63	6,32	3,64	27	3,2	1481	121,72	8,66	5,46	28
WSD3093-Hexadecasaccharides	1,64	1523	247,88	4,24	2,6	17	2,42	1530	167,22	6,06	3,64	27	3,2	1499	123,96	9,17	5,97	28
Mean	1,64	1550,50	246,80	4,24	2,60	18,50	2,55	1544,50	162,93	6,19	3,64	27,00	3,20	1490,00	122,84	8,92	5,72	28,00
SD	0,00	38,89	1,53	0,00	0,00	2,12	0,18	20,51	6,07	0,18	0,00	0,00	0,00	12,73	1,59	0,36	0,36	0,00
CV %	0	3	1	0	0	11	7	1	4	3	0	0	0	1	1	4	6	0
Variation versus not heparinoid added PRP %	9	-4	-21	19	-69	16	13	-3	-22	6	-56	32	-2	-5	-25	7	-31	20
Variation versus Enoxaparine added PRP %	18	11	-11	23	-58	9	34	9	-24	30	-41	54	19	6	-30	44	-8	30
WSD3093->=Hexadecasaccharides	1,5	1614	316,89	3,5	2	17	2	1576	266,27	4,75	2,75	16	3,43	1579	132,65	9,63	6,2	26
WSD3093->=Hexadecasaccharides	1,5	1530	324,1	3,25	1,75	14	2	1570	267,91	4,5	2,5	18	3,43	1659	135,38	9,37	5,94	28
Mean	1,50	1572,00	320,00	3,38	1,88	15,50	2,00	1573,00	267,09	4,63	2,63	16,00	3,43	1619,00	134,02	9,50	6,07	27,00
SD	0,00	59,40	5,81	0,18	0,18	2,12	0,00	4,24	1,16	0,18	0,18	0,00	0,00	56,57	1,93	0,18	0,18	1,41
CV %	0	4	2	5	9	14	0	0	0	4	7	0	0	3	1	2	3	5
Variation versus not heparinoid added PRP %	0	-3	2	-5	-77	-3	-11	-1	28	-20	-68	-22	6	3	-18	14	-27	16
Variation versus Enoxaparine added PRP %	8	12	15	-2	-70	-9	5	11	25	-3	-58	-9	28	15	-23	54	-2	26
DIA2844-Hexasaccharides	1,5	1406	284,76	3,5	2	14	1,75	1549	239,82	4,25	2,5	25	2,5	1342	188,6	6,25	3,75	19
DIA2844-Hexasaccharides	1,5	1410	291,23	3,25	1,75	18	2	1322	233,76	4,5	2,5	19	2,81	1314	125,59	8,09	5,17	27
Mean	1,50	1408,00	288,00	3,38	1,88	16,00	1,88	1435,50	236,79	4,38	2,50	21,50	2,71	1328,00	156,10	7,17	4,46	23,00
SD	0,00	2,83	4,57	0,18	0,18	2,83	0,18	160,51	4,29	0,18	0,00	4,95	0,29	19,80	43,14	1,29	1,00	5,66
CV %	0	0	2	5	9	18	9	11	2	4	0	23	11	1	28	18	23	25
Variation versus not heparinoid added PRP %	0	-13	-8	-5	-77	0	-17	-10	13	-25	-70	5	-17	-16	-4	-14	-46	-1
Variation versus Enoxaparine added PRP %	8	0	4	-2	-70	-6	-1	1	11	-8	-60	23	1	-6	-10	16	-28	7
DIA2844-Octasaccharides	1,9	1668	269,79	4,23	2,33	22	2,94	1580	189,91	6,3	3,36	26	3,45	1634	201,84	7,08	3,63	23
DIA2844-Octasaccharides	1,9	1696	278,89	3,97	2,07	23	2,68	1654	199,62	6,04	3,36	24	3,45	1624	181,75	7,85	4,4	28
Mean	1,90	1682,00	274,34	4,10	2,20	22,50	2,81	1617,00	194,87	6,17	3,36	25,00	3,45	1629,00	191,30	7,47	4,02	24,50
SD	0,00	19,80	7,14	0,18	0,18	0,71	0,18	52,33	6,87	0,18	0,00	1,41	0,00	7,07	28,35	0,54	0,54	2,12
CV %	0	1	3	4	8	3	7	3	4	3	0	6	0	0	16	7	14	9
Variation versus not heparinoid added PRP %	27	4	-12	15	-74	41	25	2	-7	6	-60	22	6	4	12	-10	-52	5
Variation versus Enoxaparine added PRP %	37	20	-1	18	-64	32	48	14	-9	30	-46	43	29	16	4	21	-35	14
DIA2844-Decasaccharides	1,9	1659	279,33	3,97	2,07	18	2,68	1629	186,44	6,3	3,62	24	3,45	1571	151,59	7,85	4,4	25
DIA2844-Decasaccharides	1,9	1704	264,62	4,23	2,33	25	2,42	1715	215,98	5,78	3,36	26	3,18	1735	164,97	7,85	4,68	28
Mean	1,90	1681,50	272,08	4,10	2,20	21,50	2,55	1672,00	201,21	6,04	3,49	25,00	3,32	1653,00	158,28	7,85	4,53	26,50
SD	0,00	31,82	10,26	0,18	0,18	4,95	0,18	60,81	20,89	0,37	0,18	1,41	0,18	115,97	9,47	0,00	0,18	2,12
CV %	0	2	4	4	8	23	7	4	10	6	5	6	6	7	6	0	4	8
Variation versus not heparinoid added PRP %	27	4	-13	15	-74	34	13	5	-4	4	-58	22	2	5	-3	-6	-46	14
Variation versus Enoxaparine added PRP %	37	20	-2	18	-64	25	34	17	-6	27	-44	43	24	18	-5	27	-27	23
DIA2844-Dodecasaccharides	1,87	1707	272,27	4,46	2,59	19	2,65	1752	195,19	6,78	4,13	22	3,42	1658	148,56	8,33	4,91	27
DIA2844-Dodecasaccharides	1,87	1724	269,89	4,46	2,59	19	2,91	1655	172,95	6,78	3,87	24	3,68	1641	142,87	9,11	5,43	26
Mean	1,87	1715,50	271,08	4,46	2,59	19,00	2,78	1703,50	184,07	6,78	4,00	23,00	3,55	1649,50	145,72	8,72	5,17	26,50
SD	0,00	12,02	1,68	0,00	0,00	0,00	0,18	68,59	15,73	0,00	0,18	1,41	0,18	12,02	4,02	0,55	0,37	0,71
CV %	0	1	1	0	0	0	7	4	9	0	5	6	5	1	3	8	7	3
Variation versus not heparinoid added PRP %	25	6	-13	25	-69	19	24	7	-12	17	-52	12	5	5	-11	5	-38	14
Variation versus Enoxaparine added PRP %	35	22	-2	29	-58	12	46	20	-14	43	-35	31	32	17	-16	41	-16	23
DIA2844-Hexadecasaccharides	1,87	1789	277,05	4,46	2,59	23	2,65	1710	198,53	6,01	3,36	24	3,17	1707	168,22	7,66	4,39	25
DIA2844-Hexadecasaccharides	1,87	1670	282,21	4,2	2,33	17	2,39	1727	202,91	6,01	3,62	27	3,17	1671	159,37	7,82	4,65	25
Mean	1,87	1729,50	279,63	4,33	2,46	20,00	2,52	1718,50	200,72	6,01	3,49	25,50	3,17	1689,00	163,80	7,89	4,52	25,00
SD	0,00	84,15	3,85	0,18	0,18	4,24	0,18	12,02	3,10	0,00	0,18	2,12	0,00	25,46	6,26	0,18	0,18	0,00
CV %	0	5	1	4	7	21	7	1	2	0	5	8	0	2	4	2	4	0
Variation versus not heparinoid added PRP %	25	7	-11	22	-70	25	12	8	-4	3	-58	24	-2	7	1	-7	-46	8
Variation versus Enoxaparine added PRP %	35	23	1	25	-60	18	33	21	-6	27	-44	46	18	20	-6	24	-27	16
DIA2844->=Hexadecasaccharides	1,75	1610	265,2	4	2,25	24	2,5	1431	181,58	5,5	3	22	3	1395	141,75	7,25	4,25	26
DIA2844->=Hexadecasaccharides	1,75	1450	267,78	3,75	2	16	2,25	1386	184,29	5,5	3,25	21	3,25	1358	143,06	7,25	4	26
Mean	1,75	1530,00	266,49	3,88	2,13	20,00	2,38	1408,50	182,93	5,50	3,13	21,50	3,13	1376,50	142,41	7,25	4,13	26,00
SD	0,00	113,14	1,62	0,18	0,18	5,66	0,18	31,82	1,91	0,00	0,18	0,71	0,18	28,18	0,93	0,00	0,18	0,00
CV %	0	7	1	5	8	28	7	2	1	0	6	3	6	2	1	0	4	0
Variation versus not heparinoid added PRP %	17	-5	-15	9	-74	25	6	-11	-12	-5	-62	5	-4	-12	-13	-13	-50	12
Variation versus Enoxaparine added PRP %	26	9	-4	12	-60	18	25	-1	-14	16	-49	23	17	-2	-18	17	-33	21

	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail
	1,5	1537	312,5	3,5	2	16	2,25	1593	204,07	6	3,75	21	3,25	1582	159,26	8,5	5,25	24
	1,5	1661	306,53	3,75	2,25	16	2,25	1621	209,86	6	3,75	21	3,25	1592	160,21	8,5	5,25	23
	1,5	1636	314,36	3,5	2	16	2,25	1614	210,32	5,75	3,5	20	3,25	1589	175,57	8	4,75	22
	1,5	1535	315,7	3,5	2	16	2,25	1517	211,37	5,5	3,25	20	3,25	1529	156,84	8,25	5	24
Mean	1,50	1617,25	312,77	3,56	2,06	16,00	2,25	1586,25	208,91	5,81	3,56	20,50	3,25	1572,50	162,97	8,31	5,06	23,25
SD	0,00	56,04	3,12	0,13	0,13	0,00	0,00	47,68	3,26	0,24	0,24	0,58	0,00	33,37	8,52	0,24	0,24	0,96
CV %	0	3	1	4	6	0	0	3	2	4	7	3	0	2	5	3	5	4

Tested molecule	PRP + HEPARINOID 1 µg / mL																	
	With Hemoliance Recombiplastin 1/40 diluted						With Hemoliance Recombiplastin 1/100 diluted						With Hemoliance Recombiplastin 1/200 diluted					
	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail
Enoxaparine	1,39	1483	296,55	3,46	2,07	14	1,9	1505	226,65	4,75	2,85	18	2,42	1472	184,23	6,31	3,89	20
Enoxaparine	1,39	1507	303,3	3,2	1,81	15	1,9	1513	232,88	4,49	2,59	17	1,64	1503	192,6	6,05	4,41	16
Mean	1,39	1485,00	294,93	3,33	1,94	14,50	1,90	1509,00	229,77	4,62	2,72	17,50	2,03	1487,50	188,42	6,18	4,15	18,00
SD	0,00	31,11	11,84	0,18	0,16	0,71	0,00	5,66	4,41	0,18	0,18	0,71	0,56	21,92	5,92	0,18	0,97	2,83
CV %	0	2	4	6	9	5	0	0	2	4	7	4	27	1	3	3	9	16
Variation versus not heparinoid added PRP %	-7	-8	-6	-7	-77	-9	-16	-5	10	-21	-67	-15	-38	-5	16	-26	-50	-23
WSD3093-Hexasaccharides	1,39	1449	285,85	3,46	2,07	14	1,9	1364	202,7	4,75	2,85	17	2,42	1418	175,96	6,05	3,63	21
WSD3093-Hexasaccharides	1,39	1387	271,32	3,46	2,07	14	2,16	1404	206,68	4,75	2,59	17	2,68	1433	172,45	6,31	3,63	23
Mean	1,39	1418,00	278,59	3,46	2,07	14,00	2,03	1384,00	204,69	4,75	2,72	17,00	2,55	1425,50	174,21	6,18	3,63	22,00
SD	0,00	43,84	10,27	0,00	0,00	0,00	0,18	28,28	2,81	0,00	0,18	0,00	0,18	10,61	2,48	0,18	0,00	1,41
CV %	0	3	4	0	0	0	9	2	1	0	7	0	7	1	1	3	0	6
Variation versus not heparinoid added PRP %	-7	-12	-11	-3	-75	-13	-10	-13	-2	-18	-67	-17	-22	-9	7	-26	-56	-5
Variation versus Enoxaparine added PRP %	0	-5	-6	4	-67	-3	7	-8	-11	3	-58	-3	26	-4	-8	0	-41	22
WSD3093-Octasaccharides	1,64	1530	280,91	3,71	2,07	17	2,16	1508	234,48	5	2,94	16	2,68	1510	193,58	6,55	3,87	19
WSD3093-Octasaccharides	1,38	1497	290,25	3,45	2,07	16	2,16	1543	210,25	5,52	3,36	19	2,68	1512	191,11	6,55	3,87	19
Mean	1,51	1513,50	285,58	3,58	2,07	16,50	2,16	1525,50	222,37	5,26	3,19	17,50	2,68	1511,00	192,35	6,55	3,87	18,50
SD	0,18	23,33	6,60	0,18	0,00	0,71	0,00	24,75	17,13	0,37	0,37	2,12	0,00	1,41	1,75	0,00	0,00	0,71
CV %	12	2	2	5	0	4	0	2	8	7	12	12	0	0	1	0	0	4
Variation versus not heparinoid added PRP %	1	-6	-9	0	-75	3	-4	-4	6	-10	-63	-15	-18	-4	18	-21	-53	-20
Variation versus Enoxaparine added PRP %	9	2	-3	3	-67	14	14	1	-3	14	-50	0	32	2	2	6	-37	3
WSD3093-Decasaccharides	1,38	1517	289,09	3,45	2,07	16	1,75	1483	293,67	4	2,25	13	2,68	1484	204,82	6,55	3,87	19
WSD3093-Decasaccharides	1,38	1555	282,7	3,71	2,33	21	2,16	1480	218,16	5,26	3,1	18	2,68	1501	201,01	6,3	3,62	21
Mean	1,38	1536,00	285,90	3,58	2,20	18,50	1,96	1481,50	255,92	4,63	2,68	15,50	2,68	1492,50	202,82	6,43	3,75	20,00
SD	0,00	26,87	4,52	0,18	0,19	3,54	0,29	2,12	53,39	0,89	0,60	3,54	0,00	12,02	2,55	0,18	0,18	1,41
CV %	0	2	2	5	8	18	15	0	21	18	22	23	0	1	1	3	5	7
Variation versus not heparinoid added PRP %	-8	-5	-9	0	-74	16	-13	-8	23	-20	-68	-24	-18	-5	24	-23	-55	-14
Variation versus Enoxaparine added PRP %	-1	3	-3	8	-64	28	3	-3	11	0	-57	-11	32	0	8	4	-39	11
WSD3093-Dodecasaccharides	1,64	1665	275,24	3,98	2,34	18	2,42	1608	172,45	6,32	3,9	22	3,2	1704	145,32	8,92	5,72	26
WSD3093-Dodecasaccharides	1,64	1623	278,11	3,98	2,34	18	2,42	1759	177,4	6,32	3,9	23	3,46	1643	138,59	9,43	5,97	27
Mean	1,64	1644,00	275,62	3,98	2,34	18,00	2,42	1683,50	174,93	6,32	3,90	22,50	3,33	1673,50	141,96	9,18	5,85	26,50
SD	0,00	29,70	3,44	0,00	0,00	0,00	0,00	106,77	3,50	0,00	0,00	0,71	0,18	43,13	4,76	0,36	0,18	0,71
CV %	0	2	1	0	0	0	0	6	2	0	0	3	6	3	3	4	3	3
Variation versus not heparinoid added PRP %	9	2	-12	12	-72	13	8	6	-16	9	-53	10	2	6	-13	10	-30	14
Variation versus Enoxaparine added PRP %	18	11	-7	20	-62	24	27	12	-24	37	-37	29	64	13	-25	48	-5	47
WSD3093-<Hexadecasaccharides	1,64	1536	259,75	3,98	2,34	15	2,42	1539	160,08	6,32	3,9	23	3,2	1418	115,65	9,43	6,23	27
WSD3093-<Hexadecasaccharides	1,39	1539	262,11	3,98	2,59	15	2,42	1564	160,69	6,06	3,64	25	3,2	1395	114,14	9,43	6,23	26
Mean	1,52	1537,50	260,93	3,98	2,47	15,00	2,42	1551,50	160,39	6,19	3,77	24,00	3,20	1407,00	114,90	9,43	6,23	26,50
SD	0,18	2,12	1,67	0,00	0,18	0,00	0,00	17,68	0,43	0,18	0,18	1,41	0,00	18,97	1,07	0,00	0,00	0,71
CV %	12	0	1	0	7	0	0	1	0	3	5	6	0	1	1	0	0	3
Variation versus not heparinoid added PRP %	1	-5	-17	12	-70	-6	8	-2	-23	6	-55	17	-2	-11	-29	13	-25	14
Variation versus Enoxaparine added PRP %	9	4	-12	20	-60	3	27	3	-30	34	-39	37	58	-5	-39	53	1	47
WSD3093->>Hexadecasaccharides	1,88	1441	222,3	4,2	2,32	21	2,85	1443	140,99	7,05	4,4	26	3,43	1375	114,48	9,63	6,2	28
WSD3093->>Hexadecasaccharides	1,88	1438	227,76	4,2	2,32	21	2,4	1438	143,42	6,63	4,13	26	3,43	1389	108,2	9,89	6,46	30
Mean	1,88	1439,50	225,03	4,20	2,32	21,00	2,53	1440,50	142,21	6,79	4,27	26,00	3,43	1382,00	111,34	9,76	6,33	29,50
SD	0,00	2,12	3,96	0,00	0,00	0,00	0,18	3,54	1,72	0,37	0,19	0,00	0,00	9,90	4,44	0,18	0,18	0,71
CV %	0	0	2	0	0	0	7	0	1	5	4	0	0	1	4	2	3	2
Variation versus not heparinoid added PRP %	25	-11	-28	18	-72	31	12	-9	-32	17	-49	27	6	-12	-32	17	-24	27
Variation versus Enoxaparine added PRP %	35	-3	-23	26	-62	45	33	-5	-38	47	-31	49	69	-7	-41	58	2	64
DIA2844-Hexasaccharides	1,88	1631	262,23	4,2	2,32	18	2,4	1531	176,88	6,01	3,61	28	3,17	1559	132,38	8,85	5,68	27
DIA2844-Hexasaccharides	1,62	1617	250,43	4,2	2,59	21	2,4	1508	167,29	6,27	3,87	23	3,17	1621	132,69	8,85	5,68	27
Mean	1,75	1624,00	256,33	4,20	2,45	19,50	2,40	1519,50	173,08	6,14	3,74	24,50	3,17	1590,00	132,54	8,85	5,68	27,00
SD	0,18	9,90	8,34	0,00	0,18	2,12	0,00	16,26	8,20	0,18	0,18	2,12	0,00	43,84	0,22	0,00	0,00	0,00
CV %	11	1	3	0	8	11	0	1	5	3	5	9	0	3	0	0	0	0
Variation versus not heparinoid added PRP %	17	0	-13	18	-71	22	7	-4	-17	8	-55	20	-2	1	-19	6	-32	16
Variation versus Enoxaparine added PRP %	26	9	-13	26	-60	34	26	1	-25	33	-39	40	58	7	-30	43	-8	50
DIA2844-Octasaccharides	1,5	1572	267,93	4	2,5	16	2,5	1472	169,86	6,25	3,75	27	3,25	1462	133,68	8,25	5	28
DIA2844-Octasaccharides	1,5	1564	279,92	3,75	2,25	15	2,5	1590	183,14	6	3,5	25	3,5	1559	133,25	8,75	5,25	28
Mean	1,50	1568,00	273,93	3,88	2,38	15,50	2,50	1531,00	176,50	6,13	3,63	26,00	3,38	1510,50	133,47	8,50	5,13	28,00
SD	0,00	6,66	8,48	0,18	0,18	0,71	0,00	83,44	9,39	0,18	0,18	1,41	0,18	68,59	0,30	0,35	0,18	0,00
CV %	0	0	3	5	7	5	0	5	5	3	5	5	5	5	0	4	3	0
Variation versus not heparinoid added PRP %	0	-3	-12	9	-71	-3	11	-3	-16	5	-56	27	4	-4	-18	2	-38	20
Variation versus Enoxaparine added PRP %	8	6	-7	16	-62	7	32	1	-23	33	-41	49	66	2	-29	38	-17	56
DIA2844-Decasaccharides	1,9	1692	265,3	4,23	2,33	20	2,68	1580	183,64	6,04	3,36	24	3,45	1565	147,8	8,63	5,18	25
DIA2844-Decasaccharides	1,9	1798	262,24	4,23	2,33	26	2,68	1591	176,86	6,3	3,62	26	3,45	1598	154,09	8,37	4,92	26
Mean	1,90	1745,00	263,77	4,23	2,33	23,00	2,68	1575,50	180,25	6,17	3,49	25,00	3,45	1581,50	151,00	8,50	5,05	25,50
SD	0,00	74,95	2,16	0,00	0,00	4,24	0,00	21,92	4,79	0,18	0,18	1,41	0,00	23,33	4,38	0,18	0,18	0,71
CV %	0	4	1	0	0	18	0	1	3	3	5	6	0	1	3	2	4	3
Variation versus not heparinoid added PRP %	27	8	-16	19	-72	44	19	-1	-14	6	-58	22	6	1	-7	2	-39	19
Variation versus Enoxaparine added PRP %	37	18	-11	27	-62	59	41	4	-22	34	-44	43	70	6	-20	38	-13	42
DIA2844-Dodecasaccharides	1,87	1712	257,87	4,46	2,59	24	2,65	1692	180,4	6,27	3,62	28	3,42	1623	147,81	8,08	4,66	28
DIA2844-Dodecasaccharides	1,87	1685	270,4	4,2	2,33	20	2,65	1759	169,09	6,78	4,13	26	3,17	1632	170,95	7,56	4,39	22
Mean	1,87	1698,50	264,14	4,33	2,46	22,00	2,65	1725,50	174,25	6,53	3,88	26,00	3,30	1627,50	159,38	7,82	4,53	24,00
SD	0,00	19,09	8,96	0,18	0,18	2,83	0,00	47,38	8,70	0,36	0,36	0,00	0,18	6,36	16,36	0,37	0,19	2,83
CV %	0	1	3	4	7	13	0	3	5	6	9	0	5	0	10	5	4	12
Variation versus not heparinoid added PRP %	25	5	-16	22	-70	38	18	9	-17	12	-53	27	1	3	-2	-6	-46	3
Variation versus Enoxaparine added PRP %	35	14	-18	30	-60	52	39	14	-24	41	-37	49	62	9	-15	27	-27	33
DIA2844-<Hexadecasaccharides	1,87	1747	278,76	4,2	2,33	18	2,65	1664	187,31	6,27	3,62	21	3,42	1759	153,35	8,33	4,91	27
DIA2844-<Hexadecasaccharides	1,87	1699	271,41	4,2	2,33	19	2,39	1667	192,3	6,01	3,62	23	3,17	1652	169,16	7,82	4,65	24
Mean	1,87	1723,00	275,58	4,20	2,33	18,50	2,52	1665,50	189,81	6,14	3,62	22,00	3,30	1705,50	161,26	8,08	4,78	25,50
SD	0,00	33,94	5,90	0,00	0,00	0,71	0,18	2,12	3,53	0,18	0,00	1,41	0,18	75,66	11,18	0,36	0,18	2,12
CV %	0	2	2	0	0	4	7	0	2	3	0	6	5	4	7	4	4	8
Variation versus not heparinoid added PRP %	25	7	-12	18	-72	16	12	5	-9	8	-56	7	1	8	-1	-3	-42	18
Variation versus Enoxaparine added PRP %	35	16	-7	26	-62	28	33	10	-17	33	-41	26	62	15	-14	31	-23	42
DIA2844->>Hexadecasaccharides	1,75	1369	251,34	3,75	2	17	2,5	1329	153,95	6	3,5	24	3,25	1406	132,83	7,75	4,5	26
DIA2844->>Hexadecasaccharides	1,75	1354	253,93	3,75	2	18	2,25	1307	175,7	5,25	3	22	3,5	1336	114,88	8,5	5	28
Mean	1,75	1361,50	252,64	3,75	2,00	17,50	2,38	1318,00	164,83	5,63	3,25	23,00	3,38	1371,00	123,86	8,13	4,75	27,00
SD	0,00	10,61	1,83	0,00	0,00	0,71	0,18	15,56	15,38	0,53	0,35	1,41	0,18	49,50	12,69	0,53	0,35	1,41
CV %	0	1	1	0	0	4	7	1	9	9	11	6	5	4	10	7	7	5
Variation versus not heparinoid added PRP %	17	-16	-19	5	-76	8	6	-17	-21	-3	-61	12	4	-13	-24	-2	-43	16
Variation versus Enoxaparine added PRP %	26	-8	-14	13	-68	21	25	-13	-28	22	-47	31	66	-8	-34	31	23	50

	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail
	1,5	1637	312,5	3,5	2	16	2,25	1593	204,07	6	3,75	21	3,25	1582	159,26	8,5	5,25	24
	1,5	1661	309,63	3,75	2,25	16	2,25	1621	209,98	6	3,75	21	3,25	1592	160,21	8,5	5,25	23
	1,5	1636	314,56	3,5	2	16	2,25	1614	210,32	5,75	3,5	20	3,25	1593	175,57	8	4,75	22
	1,5	1535	315,7	3,5	2	16	2,25	1517	211,37	5,5	3,25	20	3,25	1523	156,64	8,25	5	24
Mean	1,50	1617,25	312,77	3,56	2,06	16,00	2,25	1586,25	208,91	5,81	3,56	20,50	3,25	1572,50	162,97	8,31	5,06	23,25
SD	0,00	58,04	3,12	0,13	0,13	0,00	0,00	47,68	3,28	0,24	0,24	0,58	0,00	33,37	8,62	0,24	0,24	0,96
CV %	0	3	1	4	6	0	0	3	2	4	7	3	0	2	5	3	5	4

Tested molecule	PRP + HEPARINOID 2,5 µg / mL																	
	With Hemoliance Recombiplastin 1/49 diluted						With Hemoliance Recombiplastin 1/100 diluted						With Hemoliance Recombiplastin 1/200 diluted					
	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail
Enoxaparine	1,39	1296	250,57	3,2	1,81	18	1,64	1323	183,26	5,01	3,37	16,14	2,68	1314	139,84	7,35	4,67	24
Enoxaparine	1,25	1547	383,53	3	1,75	16	1,64	1323	173,62	5,01	3,37	18	2,5	1467	225,81	6,25	3,75	20
Mean	1,32	1421,50	367,05	3,10	1,78	17,00	1,64	1323,00	178,44	5,01	3,37	17,07	2,59	1390,50	182,83	6,80	4,21	22,00
SD	0,10	177,48	79,87	0,14	0,04	1,41	0,00	0,00	6,91	0,00	0,00	1,32	0,13	108,19	60,79	0,78	0,65	2,83
CV %	7	12	26	5	2	8	0	0	4	0	0	8	5	8	33	11	16	13
ation versus not heparinoid added PRP %	-12	-12	-2	-13	-79	6	-27	-17	-15	-14	-59	-17	-20	-12	12	-18	-49	-5
WSD3093-Hexasaccharides	1,39	1401	262,74	3,46	2,07	16	2,16	1319	185,23	5,27	3,11	18	2,68	1435	170,85	6,57	3,89	21
WSD3093-Hexasaccharides	1,39	1424	273,41	3,2	1,81	15	1,9	1433	202,18	4,75	2,85	19	2,68	1498	170,63	6,83	4,15	22
Mean	1,39	1412,50	268,08	3,33	1,94	15,50	2,03	1376,00	193,71	5,01	2,98	18,50	2,68	1466,50	170,79	6,70	4,02	21,50
SD	0,00	16,26	7,54	0,18	0,18	0,71	0,18	80,61	11,89	0,37	0,18	0,71	0,00	44,55	0,23	0,18	0,18	0,71
CV %	0	1	3	6	9	5	9	6	6	7	6	4	0	3	0	3	5	3
ation versus not heparinoid added PRP %	-7	-13	-14	-7	-77	-3	-10	-13	-7	-14	-64	-10	-18	-7	5	-19	-52	-8
iation versus Enoxaparine added PRP %	5	-1	-13	7	-71	-9	24	4	9	0	-56	8	3	5	-7	-1	-41	-2
WSD3093-Octasaccharides	1,38	1523	275,3	3,45	2,07	17	2,16	1532	203,97	5,52	3,36	19	2,68	1503	182,9	6,81	4,13	20
WSD3093-Octasaccharides	1,38	1521	276,7	3,45	2,07	17	2,16	1538	205,97	5,52	3,36	18	2,94	1520	180,68	7,07	4,13	23
Mean	1,38	1522,00	276,00	3,45	2,07	17,00	2,16	1535,00	204,97	5,52	3,36	19,00	2,81	1511,50	181,79	6,94	4,13	21,50
SD	0,00	1,41	0,99	0,00	0,00	0,00	0,00	4,24	1,41	0,00	0,00	0,00	0,19	12,02	1,57	0,18	0,00	2,12
CV %	0	0	0	0	0	0	0	0	1	0	0	0	7	1	1	3	0	10
ation versus not heparinoid added PRP %	-8	-6	-12	-3	-75	6	-4	-3	-2	-5	-60	-7	-14	-4	12	-17	-50	-8
iation versus Enoxaparine added PRP %	5	7	-10	11	-70	0	32	16	15	10	-51	11	8	9	-1	2	-39	-2
WSD3093-Decasaccharides	1,38	1597	280,77	3,71	2,33	17	2,16	1537	209,3	5,52	3,36	20	2,94	1456	182,64	7,07	4,13	19
WSD3093-Decasaccharides	1,38	1548	278,75	3,45	2,07	18	1,9	1509	213,47	5,52	3,62	18	2,94	1489	183,91	7,07	4,13	20
Mean	1,38	1572,50	280,26	3,58	2,20	17,50	2,03	1523,00	211,39	5,52	3,49	19,00	2,94	1472,00	183,38	7,07	4,13	19,50
SD	0,00	34,65	0,72	0,18	0,18	0,71	0,18	19,80	2,85	0,00	0,18	1,41	0,00	22,63	0,78	0,00	0,00	0,71
CV %	0	2	0	5	8	4	9	1	1	0	5	7	0	2	0	0	0	4
ation versus not heparinoid added PRP %	-8	-3	-10	0	-74	9	-10	-4	1	-5	-58	-7	-10	-5	13	-15	-50	-16
iation versus Enoxaparine added PRP %	5	11	-9	15	-68	3	24	15	18	10	-49	11	14	6	0	4	-39	-11
WSD3093-Dodecasaccharides	1,64	1483	215,62	4,24	2,6	20	2,42	1352	110,15	7,62	5,2	29	3,2	1412	114,2	9,95	6,75	29
WSD3093-Dodecasaccharides	1,39	1478	223,24	3,98	2,59	18	2,42	1420	120,71	7,38	4,84	28	3,2	1397	118,89	9,17	5,87	27
Mean	1,52	1480,50	219,43	4,11	2,80	19,00	2,42	1386,00	115,43	7,49	5,07	28,50	3,20	1404,50	116,55	9,56	6,36	28,00
SD	0,18	3,54	5,39	0,18	0,01	1,41	0,00	48,08	7,47	0,18	0,18	0,71	0,00	10,61	3,32	0,55	0,55	1,41
CV %	12	0	2	4	0	7	0	3	6	2	4	2	0	1	3	6	9	5
iation versus not heparinoid added PRP %	1	-8	-30	15	-69	19	8	-13	-45	20	-39	39	-2	-11	-28	15	-23	20
iation versus Enoxaparine added PRP %	15	4	-29	33	-62	12	48	5	-35	50	-25	67	24	1	-36	41	-6	27
WSD3093-<Hexadecasaccharides	1,64	1690	238,96	4,24	2,6	20	2,16	1472	145,14	6,58	4,42	23	3,46	1413	109,99	10,21	6,75	32
WSD3093-<Hexadecasaccharides	1,39	1592	235,34	4,24	2,85	20	2,16	1435	140,7	6,84	4,68	23	3,2	1413	110,85	9,69	6,49	29
Mean	1,52	1636,00	237,15	4,24	2,73	20,00	2,16	1453,50	142,92	6,71	4,55	23,00	3,33	1413,00	110,42	9,95	6,62	30,50
SD	0,18	62,23	2,56	0,00	0,18	0,00	0,00	26,16	3,14	0,18	0,18	0,00	0,18	0,00	0,61	0,37	0,18	2,12
CV %	12	4	1	0	6	0	0	2	2	3	4	0	6	0	1	4	3	7
iation versus not heparinoid added PRP %	1	1	-24	19	-67	25	-4	-8	-32	15	-45	12	2	-10	-32	20	-20	31
iation versus Enoxaparine added PRP %	15	15	-23	37	-60	18	32	10	-20	34	-33	35	29	2	-40	46	-3	39
WSD3093->=Hexadecasaccharides	1,62	1346	174,7	4,46	2,84	28	2,91	1215	89,71	8,34	5,43	33	4,46	1122	82,16	11,95	7,49	33
WSD3093->=Hexadecasaccharides	1,62	1314	180,81	4,46	2,84	27	2,91	1203	93,5	8,85	5,94	30	4,2	958	85,87	11,69	7,48	33
Mean	1,62	1330,00	177,76	4,46	2,84	27,50	2,91	1209,00	91,61	8,60	5,69	31,50	4,33	1040,00	74,01	11,82	7,49	33,00
SD	0,00	22,63	4,32	0,00	0,00	0,71	0,00	6,49	2,68	0,36	0,36	2,12	0,18	115,97	11,51	0,18	0,00	0,00
CV %	0	2	2	0	0	3	0	1	3	4	6	7	4	11	16	2	0	0
iation versus not heparinoid added PRP %	8	-18	-43	25	-66	72	29	-24	-56	48	-32	54	33	-34	-55	42	-10	42
iation versus Enoxaparine added PRP %	23	-6	-42	44	-58	62	77	-9	-49	72	-16	85	67	-25	-69	74	10	50
DIA2844-Hexasaccharides	1,88	1677	243,51	4,72	2,84	19	2,4	1649	165,63	8,53	4,13	26	3,43	1440	120,78	8,37	5,84	30
DIA2844-Hexasaccharides	1,62	1626	258,47	4,2	2,58	18	2,4	1616	171,12	8,53	4,13	24	2,85	1511	127,08	8,85	6,2	23
Mean	1,75	1651,50	250,99	4,46	2,71	18,50	2,40	1632,50	168,38	8,53	4,13	25,00	3,04	1475,50	123,93	8,11	6,07	26,50
SD	0,18	36,06	10,58	0,37	0,18	0,71	0,00	23,33	3,88	0,00	0,00	1,41	0,55	50,20	4,45	0,37	0,18	4,95
CV %	11	2	4	8	7	4	0	1	2	0	0	6	18	3	4	4	3	19
iation versus not heparinoid added PRP %	17	2	-20	25	-67	16	7	3	-19	12	-50	22	-5	-5	-24	10	-27	14
iation versus Enoxaparine added PRP %	33	16	-18	44	-60	9	46	23	-6	30	-39	46	17	6	-32	34	-11	20
DIA2844-Octasaccharides	1,64	1605	248,63	4,23	2,59	21	2,68	1652	159,98	7,08	4,4	31	3,71	1597	140,47	9,66	5,95	28
DIA2844-Octasaccharides	1,64	1679	252,52	4,23	2,59	20	2,68	1688	175,57	6,82	4,14	28	3,45	1589	139,49	9,4	5,95	28
Mean	1,64	1642,00	250,58	4,23	2,59	20,50	2,68	1666,00	167,72	6,95	4,27	29,50	3,58	1593,00	139,98	9,53	5,95	28,00
SD	0,00	52,33	2,75	0,00	0,00	0,71	0,00	11,31	11,11	0,18	0,18	3,54	0,18	19,80	0,69	0,18	0,00	0,00
CV %	0	3	1	0	0	3	0	1	7	3	4	12	5	1	0	2	0	0
ariation versus not heparinoid added PRP %	9	2	-20	19	-69	28	19	5	-20	20	-49	39	10	1	-14	15	-28	12
Variation versus Enoxaparine added PRP %	24	16	-18	38	-62	21	63	25	-6	39	-37	67	38	14	-23	40	-13	18
DIA2844-Decasaccharides	1,9	1664	241,18	4,75	2,85	21	2,68	1665	162,55	6,82	4,14	27	3,45	1603	164,3	8,11	4,68	25
DIA2844-Decasaccharides	1,64	1698	257,71	4,49	2,85	18	2,68	1531	162,21	6,82	4,14	28	3,71	1564	139,55	9,66	5,95	30
Mean	1,77	1681,00	249,45	4,62	2,85	19,50	2,68	1598,00	162,38	6,82	4,14	26,50	3,58	1583,50	151,93	8,89	5,31	27,50
SD	0,18	24,04	11,69	0,18	0,00	2,12	0,00	94,75	0,24	0,00	0,00	0,71	0,18	27,58	17,50	1,10	0,81	3,54
CV %	10	1	5	4	0	11	0	6	0	0	0	3	5	2	12	12	17	13
ariation versus not heparinoid added PRP %	18	4	-20	30	-66	22	19	1	-22	17	-50	29	10	1	-7	7	-36	18
Variation versus Enoxaparine added PRP %	34	18	-19	49	-58	15	63	21	-9	35	-39	55	38	14	-17	31	-22	25
DIA2844-Dodecasaccharides	1,62	1579	247,36	4,2	2,58	20	2,65	1639	152,48	7,04	4,39	27	3,94	1452	109,16	10,4	6,46	31
DIA2844-Dodecasaccharides	1,62	1588	234,47	4,2	2,58	20	2,65	1595	154,52	7,04	4,39	26	3,68	1613	138,39	9,88	6,2	28
Mean	1,62	1583,50	240,92	4,20	2,58	20,00	2,65	1617,00	153,50	7,04	4,39	26,50	3,81	1532,50	123,78	10,14	6,33	29,50
SD	0,00	6,36	9,11	0,00	0,00	0,00	0,00	31,11	1,44	0,00	0,00	0,71	0,18	113,84	20,67	0,37	0,18	2,12
CV %	0	0	4	0	0	0	0	2	1	0	0	3	5	7	17	4	3	7
ariation versus not heparinoid added PRP %	8	-2	-23	18	-69	25	18	2	-27	21	-47	29	17	-3	-24	22	-24	27
Variation versus Enoxaparine added PRP %	23	11	-22	35	-62	18	62	22	-14	41	-35	55	47	10	-32	49	-7	34
DIA2844-<Hexadecasaccharides	1,87	1689	255,82	4,48	2,59	19	2,65	1679	166,71	7,04	4,39	28	3,42	1630	138,7	9,11	6,69	30
DIA2844-<Hexadecasaccharides	1,62	1861	259,3	4,2	2,59	18	2,39	1597	164,1	6,52	4,13	24	3,42	1633	140,41	9,63	6,21	27
Mean	1,75	1875,00	257,56	4,33	2,59	18,50	2,52	1823,00	165,41	6,78	4,26	26,00	3,42	1631,50	139,56	9,37	5,95	28,50
SD	0,18	18,90	2,48	0,18	0,01	0,71	0,18	79,20	1,85	0,37	0,18	2,83	0,00	2,12	2,62	0,37	0,37	2,12
CV %	10	1	1	4	0	4	7	5	1	5	4	11	0	0	2	4	6	7
ariation versus not heparinoid added PRP %	16	4	-18	22	-69	18	12	2	-21	17	-49	27	5	4	-15	13	-28	23
Variation versus Enoxaparine added PRP %	32	18	-16	40	-62	9	54	23	-7	35	-37	52	32	17	-24	38	-13	30
DIA2844->=Hexadecasaccharides	1,75	976	169,7	4,25	2,5	19	3,25	965	73,69	8,5	5,26	32	4,75	817	55,37	11,75	7	32
DIA2844->=Hexadecasaccharides	1,75	984	177,17	4	2,25	20	3	964	91,19	7,25	4,25	30	4,75	938	64,49	11,75	7	34
Mean	1,75	980,00	172,94	4,13	2,38	19,50	3,13	964,50	82,44	7,88	4,75	31,00	4,75	877,50	59,93	11,75	7,00	33,00
SD	0,00	5,66	5,99	0,18	0,18	0,71	0,18	0,71	12,38	0,88	0,71	1,41	0,00	85,56	6,45	0,00	0,00	1,41
CV %	0	1	3	4	7	4	6	0	15	11	15	5	0	10	11	0	0	4
ariation versus not heparinoid added PRP %	17	-39	-45	16	-71	22	39	-39	-61	35	-43	51	45	-44	-63	43	-16	42
Variation versus Enoxaparine added PRP %	33	-31	-44	33	-65	15	91	-27	-54	57	-39	82	83	-37	-67	73	3	50

	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	1,5	1637	312,5	3,5	2	16	2,25	1593	204,07	6	3,75	21	3,25	1582	159,26	8,5	5,25	24
	1,5	1681	308,53	3,75	2,25	18	2,25	1621	209,86	6	3,75	21	3,25	1592	160,21	8,5	5,25	23
	1,5	1636	314,36	3,5	2	16	2,25	1614	210,32	5,75	3,5	20	3,25	1593	175,57	8	4,75	22
	1,5	1535	315,7	3,5	2	16	2,25	1617	211,37	5,5	3,25	20	3,25	1523	158,84	8,25	5	24
Mean	1,50	1617,25	312,77	3,56	2,08	16,00	2,25	1586,25	208,91	5,81	3,56	20,50	3,25	1572,50	162,97	8,31	5,06	23,25
SD	0,00	56,04	3,12	0,13	0,13	0,00	0,00	47,68	3,28	0,24	0,24	0,58	0,00	33,37	8,52	0,24	0,24	0,96
CV %	0	3	1	4	6	0	0	3	2	4	7	3	0	2	5	3	5	4

Tested molecule	PRP + HEPARINOID 5 µg / mL																	
	With Hemollance Recombiplastin 1/40 diluted						With Hemollance Recombiplastin 1/100 diluted						With Hemollance Recombiplastin 1/200 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	1,39	1090	196,46	3,46	2,07	20	2,16	1081	116,66	6,31	4,15	24	3,2	978	77,42	9,84	6,74	28
Enoxaparine	1,39	1067	179,49	3,72	2,33	23	2	1170	220,72	4,75	2,75	16	3,2	997,85	84,47	9,94	6,74	27
Mean	1,39	1078,50	187,98	3,59	2,20	21,50	2,08	1125,50	168,69	5,53	3,45	20,00	3,20	987,93	80,95	9,94	6,74	27,50
SD	0,00	16,26	12,00	0,18	0,18	2,12	0,11	62,93	73,58	1,10	0,99	5,66	0,00	14,04	4,99	0,00	0,00	0,71
CV %	0	2	6	5	8	10	5	6	44	20	29	28	0	1	6	0	0	3
tion versus not heparinoid added PRP %	-7	-33	-40	1	-74	34	-8	-29	-10	-5	-58	-2	-2	-37	-50	20	-19	18
WSD3093-Hexasaccharides	1,39	1405	258,41	3,46	2,07	16	1,9	1375	182,95	5,27	3,37	18	2,68	1411	152,4	7,09	4,41	21
WSD3093-Hexasaccharides	1,25	1476	349,85	2,75	1,5	14	1,9	1493	193,82	5,27	3,37	19	2,68	1417	151,57	7,09	4,41	24
Mean	1,32	1440,50	304,13	3,11	1,79	15,00	1,90	1434,00	188,39	5,27	3,37	18,50	2,68	1414,00	151,99	7,09	4,41	22,50
SD	0,10	50,20	64,66	0,50	0,40	1,41	0,00	83,44	7,69	0,00	0,00	0,71	0,00	4,24	0,59	0,00	0,00	2,12
CV %	7	3	21	16	23	9	0	6	4	0	0	4	0	0	0	0	0	9
tion versus not heparinoid added PRP %	-12	-11	-3	-13	-79	-6	-16	-10	-10	-9	-59	-10	-18	-10	-7	-15	-47	-3
ation versus Enoxaparine added PRP %	-5	34	62	-14	-82	-30	-9	27	12	-5	-66	-8	-16	43	88	-29	-56	-18
WSD3093-Octasaccharides	1,38	1564	249,94	3,97	2,59	20	2,16	1512	178,21	6,55	4,39	20	3,19	1493	158,82	8,11	4,92	24
WSD3093-Octasaccharides	1,64	1551	240,66	4,23	2,59	20	2,16	1535	183,42	6,3	4,14	21	3,19	1496	162,87	7,85	4,66	22
Mean	1,51	1557,50	245,25	4,10	2,59	20,00	2,16	1523,50	180,82	6,43	4,27	20,50	3,19	1494,50	160,85	7,98	4,79	23,00
SD	0,18	8,19	6,49	0,18	0,00	0,00	0,00	16,26	3,68	0,18	0,18	0,71	0,00	2,12	2,86	0,18	0,18	1,41
CV %	12	1	3	4	0	0	0	1	2	3	4	3	0	0	2	2	4	6
tion versus not heparinoid added PRP %	1	-4	-22	15	-60	25	-4	-4	-13	11	-49	0	-2	-5	-1	-4	-42	-1
ation versus Enoxaparine added PRP %	9	44	30	14	-74	-7	4	35	7	16	-57	3	0	51	99	-20	-52	-16
WSD3093-Decasaccharides	1,38	1582	260,95	3,97	2,59	17	2,16	1489	182,93	6,3	4,14	21	3,19	1432	157,06	7,85	4,66	22
WSD3093-Decasaccharides	1,38	1512	252,49	3,97	2,59	18	2,16	1530	182,58	6,3	4,14	22	2,94	1499	174,33	7,59	4,65	19
Mean	1,38	1547,00	256,72	3,97	2,59	17,50	2,16	1509,50	182,76	6,30	4,14	21,50	3,07	1465,50	165,70	7,72	4,66	20,50
SD	0,00	49,50	5,98	0,00	0,00	0,71	0,00	28,99	0,25	0,00	0,00	0,71	0,18	47,38	12,21	0,18	0,01	2,12
CV %	0	3	2	0	0	4	0	2	0	0	0	3	6	3	7	2	0	10
tion versus not heparinoid added PRP %	-3	-4	-18	11	-69	9	-4	-5	-13	8	-50	5	-6	-7	2	-7	-44	-12
ation versus Enoxaparine added PRP %	-1	43	37	11	-74	-19	4	34	8	14	-58	8	-4	48	105	-22	-53	-25
WSD3093-Dodecasaccharides	1,64	1434	196,26	4,5	2,86	24	2,42	1335	96,91	8,66	6,24	32	3,46	1166	77,83	10,99	7,53	33
WSD3093-Dodecasaccharides	1,39	1560	215,15	4,5	3,11	21	2,42	1439	119,42	7,62	5,2	29	3,46	1086	69,3	11,25	7,79	32
Mean	1,52	1497,00	205,71	4,50	2,99	22,50	2,42	1387,00	108,17	8,14	5,72	30,00	3,46	1126,00	73,57	11,12	7,66	32,50
SD	0,18	89,10	13,36	0,00	0,18	2,12	0,00	73,54	15,92	0,74	0,74	2,83	0,00	56,57	6,03	0,18	0,18	0,71
CV %	12	6	6	0	6	9	0	5	15	9	13	9	0	5	8	2	2	2
tion versus not heparinoid added PRP %	1	-7	-34	26	-64	41	8	-13	-48	46	-31	46	6	-28	-55	34	-8	40
ation versus Enoxaparine added PRP %	9	39	9	25	-70	5	16	23	-36	47	-42	50	8	14	-9	12	-23	18
WSD3093-Hexadecasaccharides	1,39	1581	203,59	4,5	3,11	22	2,42	1427	119,11	7,36	4,94	27	3,72	1172	80,1	10,99	7,27	33
WSD3093-Hexadecasaccharides	1,64	1549	208,34	4,5	2,86	24	2,16	1422	112,5	7,88	5,72	28	3,46	1235	86,87	10,73	7,27	32
Mean	1,52	1565,00	205,97	4,50	2,99	23,00	2,29	1424,50	115,81	7,62	5,33	27,50	3,59	1203,50	83,49	10,86	7,27	32,50
SD	0,18	22,63	3,36	0,00	0,18	1,41	0,18	3,54	4,67	0,37	0,55	0,71	0,18	44,55	4,79	0,18	0,00	0,71
CV %	12	1	2	0	6	6	8	0	4	5	10	3	5	4	6	2	0	2
tion versus not heparinoid added PRP %	1	-3	-34	26	-64	44	2	-10	-45	31	-38	34	10	-23	-49	31	-13	40
ation versus Enoxaparine added PRP %	9	45	10	25	-70	7	10	27	-31	38	-46	38	12	22	3	9	-27	18
093->>Hexadecasaccharides	1,88	801	82,2	5,24	3,36	29	2,91	525	31,59	11,18	8,27	34	6,27	619	35,67	15,83	9,56	36
093->>Hexadecasaccharides	1,62	807	91,38	4,98	3,36	24	3,43	780	57,08	10,4	6,97	33	6,27	632	36,3	15,83	9,56	36
Mean	1,75	804,00	86,79	5,11	3,36	26,50	3,17	652,50	44,34	10,79	7,62	33,50	6,27	625,50	35,99	15,83	9,56	36,00
SD	0,18	4,24	6,49	0,18	0,00	3,54	0,37	180,31	18,02	0,55	0,92	0,71	0,00	9,19	0,45	0,00	0,00	0,00
CV %	11	1	7	4	0	13	12	28	41	5	12	2	0	1	1	0	0	0
tion versus not heparinoid added PRP %	17	-50	-72	43	-60	66	41	-59	-78	86	-9	63	93	-60	-78	90	15	55
ation versus Enoxaparine added PRP %	26	-25	-54	42	-66	23	52	-42	-74	95	-23	68	96	-37	-56	59	-4	31
DIA2844-Hexasaccharides	1,62	1719	234,98	4,72	3,1	20	2,4	1621	156,47	6,79	4,39	25	3,69	1632	121,03	10,68	6,97	30
DIA2844-Hexasaccharides	1,62	1708	256,71	4,2	2,59	18	2,4	1644	164,93	6,79	4,39	26	3,43	1571	116,92	10,4	6,97	31
Mean	1,62	1713,50	245,35	4,46	2,84	19,00	2,40	1632,50	160,70	6,79	4,39	25,50	3,56	1601,50	118,98	10,53	6,97	30,50
SD	0,00	7,78	14,86	0,37	0,37	1,41	0,00	16,26	5,98	0,00	0,00	0,71	0,18	43,13	2,91	0,18	0,00	0,71
CV %	0	0	6	8	13	7	0	1	4	0	0	3	5	3	2	2	0	2
tion versus not heparinoid added PRP %	8	6	-22	25	-66	19	7	3	-23	17	-47	24	10	2	-27	27	-16	31
ation versus Enoxaparine added PRP %	17	59	31	24	-71	-12	15	45	-5	23	-56	28	11	62	47	6	-30	11
DIA2844-Octasaccharides	1,9	1657	230,52	4,75	2,85	23	2,94	1618	140,54	7,85	4,91	27	3,97	1555	130,34	10,18	6,21	29
DIA2844-Octasaccharides	1,9	1693	245,86	4,49	2,59	23	2,94	1614	146,4	7,85	4,91	26	3,71	1508	129,56	9,92	6,21	28
Mean	1,90	1675,00	238,19	4,62	2,72	23,00	2,94	1616,00	143,47	7,85	4,91	26,50	3,84	1531,50	129,95	10,05	6,21	28,50
SD	0,00	25,46	10,85	0,18	0,18	0,00	0,00	2,83	4,14	0,00	0,00	0,71	0,18	33,23	0,55	0,18	0,00	0,71
CV %	0	2	5	4	7	0	0	0	3	0	0	3	5	2	0	2	0	2
tion versus not heparinoid added PRP %	27	4	-24	30	-67	44	31	2	-31	35	-41	29	18	-3	-20	21	-25	23
ation versus Enoxaparine added PRP %	37	55	27	29	-73	7	41	44	-15	42	-51	33	20	55	61	1	-33	4
DIA2844-Decasaccharides	1,64	1727	246,65	4,49	2,85	20	2,94	1541	138,54	7,89	4,65	25	3,97	1497	125,42	10,44	6,47	28
DIA2844-Decasaccharides	1,64	1668	223,93	4,75	3,11	19	2,94	1545	139,18	8,37	5,43	26	3,97	1438	123,51	10,7	6,73	27
Mean	1,64	1697,50	235,29	4,62	2,98	19,50	2,94	1543,00	138,86	7,98	5,04	25,50	3,97	1467,50	124,47	10,57	6,60	27,50
SD	0,00	41,72	16,07	0,18	0,18	0,71	0,00	2,83	0,45	0,55	0,55	0,71	0,00	41,72	1,35	0,18	0,18	0,71
CV %	0	2	7	4	6	4	0	0	0	7	11	3	0	3	1	2	3	3
tion versus not heparinoid added PRP %	9	5	-25	30	-64	22	31	-3	-34	37	-39	24	22	-7	-24	27	-21	18
ation versus Enoxaparine added PRP %	18	57	25	29	-70	-9	41	37	-18	44	-49	28	24	49	54	6	-34	0
DIA2844-Dodecasaccharides	1,62	1629	221,8	4,72	3,1	23	2,91	1484	116,65	8,85	5,94	28	4,2	1814	120,17	10,68	6,46	30
DIA2844-Dodecasaccharides	1,62	1645	223,66	4,46	2,84	25	2,65	1538	131,99	7,82	5,17	29	4,46	1408	102,18	11,18	6,72	31
Mean	1,62	1636,50	222,73	4,59	2,97	24,00	2,78	1511,00	124,32	8,34	5,56	28,50	4,33	1511,00	111,18	10,92	6,59	30,50
SD	0,00	12,02	1,32	0,18	0,18	1,41	0,18	38,18	10,85	0,73	0,54	0,71	0,18	145,66	12,72	0,37	0,18	0,71
CV %	0	1	1	4	6	6	7	3	9	9	10	2	4	10	11	3	3	2
tion versus not heparinoid added PRP %	8	1	-29	29	-66	50	24	-5	-40	43	-33	39	33	-4	-32	31	-21	31
ation versus Enoxaparine added PRP %	17	52	18	28	-70	12	34	34	-26	51	-44	43	35	53	37	10	-34	11
DIA2844-Hexadecasaccharides	1,62	1756	237,96	4,72	3,1	22	2,91	1585	134,5	8,06	5,17	29	3,68	1609	123,71	10,4	6,72	28
DIA2844-Hexadecasaccharides	1,62	1739	294,04	4,46	2,84	20	2,39	1836	172,97	7,04	4,65	27	3,94	1594	125,74	10,92	6,99	30
Mean	1,62	1747,50	266,00	4,59	2,97	21,00	2,65	1709,50	153,69	7,58	4,91	28,00	3,81	1551,50	124,73	10,66	6,85	29,00
SD	0,00	12,02	39,65	0,18	0,18	1,41	0,37	178,90	27,13	0,74	0,37	1,41	0,18	60,10	1,44	0,37	0,18	1,41
CV %	0	1	15	4	6	7	14	10	18	10	7	5	5	4	1	3	3	5
tion versus not heparinoid added PRP %	8	8	-15	29	-64	31	18	8	-26	39	-41	37	17	-1	-23	28	-18	25
ation versus Enoxaparine added PRP %	17	62	42	28	-70	-2	27	52	-9	37	-51	40	19	57	54	7	-31	5
DIA2844->>Hexadecasaccharides	2	594	73,4	5	3	27	4,5	348	22,7	11	6,5	32	9	424	25,93	18,75	9,75	35
2844->>Hexadecasaccharides	2	609	77,6	4,75	2,75	28	4	386	24,37	10,25	6,25	32	9	320	18,89	21,5	12,5	35
Mean	2,00	601,50	75,50	4,88	2,88	27,50	4,25	367,00	23,54	10,63	6,38	32,00	9,00	372,00	22,41	20,13	11,13	35,00
SD	0,00	10,61	2,97	0,18	0,18	0,71	0,35	26,87	1,18	0,53	0,18	0,00	0,00	73,54	4,99	1,94	1,94	0,00
CV %	0	2	4	4	6	3	8	7	5	5	3	0	0	20	22	10	17	0
tion versus not heparinoid added PRP %	33	-53	-75	37	-65	72	89	-77	-89	83	-23	56	177	-76	-36	142	34	51
ation versus Enoxaparine added PRP %	44	-44	-69	35	-71	28	104	-67	-86	92	-35	69	181	-52	-72	102	12	27

	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail
	1,5	1637	312,5	3,5	2	16	2,25	1593	204,07	6	3,75	21	3,25	1562	159,26	8,5	5,25	24
	1,5	1661	308,53	3,75	2,25	16	2,25	1621	209,98	6	3,75	21	3,25	1592	160,21	8,5	5,25	23
	1,5	1636	314,36	3,5	2	16	2,25	1614	210,32	5,75	3,5	20	3,25	1593	175,57	9	4,75	22
	1,5	1535	315,7	3,5	2	16	2,25	1517	211,37	5,5	3,25	20	3,25	1523	156,84	8,25	5	24
Mean	1,50	1617,25	312,77	3,56	2,06	16,00	2,25	1586,25	208,91	5,81	3,56	20,50	3,25	1572,50	162,97	8,31	5,06	23,25
SD	0,00	56,04	3,12	0,13	0,13	0,00	0,00	47,68	3,28	0,24	0,24	0,58	0,00	33,37	8,52	0,24	0,24	0,96
CV %	0	3	1	4	6	0	0	3	2	4	7	3	0	2	5	3	5	4

Tested molecule	PRP + HEPARINOID 10 µg / mL. With Hemolliance Recombiplastin 1/40 diluted						With Hemolliance Recombiplastin 1/100 diluted						With Hemolliance Recombiplastin 1/200 diluted					
	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail	Lagtime	ETP	Peak	tiPeak	tiP - LT	startTail
Enoxaparine	1,39	654	93,89	3,96	2,59	23	2,42	486	32,07	7,8	5,18	31	5,79	468	29,94	13,31	7,52	35
Enoxaparine	1,64	668	83,84	4,49	2,85	27	2,68	431	28,23	8,12	5,44	31	5,53	474	28,44	13,82	8,29	36
Mean	1,52	661,00	88,87	4,24	2,72	25,00	2,55	458,50	30,15	7,96	5,31	31,00	5,66	470,00	29,19	13,57	7,91	35,50
SD	0,18	9,90	7,11	0,36	0,18	2,83	0,18	38,89	2,72	0,37	0,18	0,00	0,18	5,66	1,06	0,36	0,54	0,71
CV %	12	1	8	9	7	11	7	8	9	5	3	0	3	1	4	3	7	2
...ation versus not heparinoid added PRP %	1	-59	-72	19	-67	56	13	-71	-86	35	-36	51	74	-70	-82	63	-5	53
WSD3093-Hexasaccharides	1,39	1447	251,22	3,46	2,07	16	1,9	1470	177,7	6,05	4,15	20	2,94	1461	144,3	7,6	4,66	23
WSD3093-Hexasaccharides	1,25	1574	355,09	3	1,75	16	1,9	1450	180,21	5,53	3,63	21	3,2	1393	134,65	8,38	5,18	24
Mean	1,32	1510,50	303,16	3,23	1,91	16,00	1,90	1460,00	178,96	5,79	3,89	20,50	3,07	1427,00	139,43	7,99	4,92	23,50
SD	0,10	89,80	73,45	0,33	0,23	0,00	0,00	14,14	1,77	0,37	0,37	0,71	0,18	48,09	6,89	0,55	0,37	0,71
CV %	7	6	24	10	12	0	0	1	1	6	9	3	6	3	5	7	7	3
...ation versus not heparinoid added PRP %	-12	-7	-3	-9	-77	0	-16	-8	-14	0	-53	0	-6	-9	-14	-4	-41	1
...iation versus Enoxaparine added PRP %	-13	129	241	-24	-86	-36	-25	218	494	-25	-71	-34	-46	204	378	-41	-64	-34
WSD3093-Octasaccharides	1,38	1037	147,79	4,49	3,11	23	2,42	982	100,33	7,33	4,91	23	3,45	938	85,05	9,4	5,95	24
WSD3093-Octasaccharides	1,38	1053	165,76	4,23	2,85	20	2,42	1006	107,88	6,81	4,39	22	3,71	971	98,71	8,62	4,91	22
Mean	1,38	1045,00	156,78	4,36	2,98	21,50	2,42	994,00	104,11	7,07	4,65	22,50	3,58	954,50	91,88	9,01	5,43	23,00
SD	0,00	11,31	12,71	0,18	0,18	2,12	0,00	16,97	5,34	0,37	0,37	0,71	0,18	23,33	9,66	0,55	0,74	1,41
CV %	0	1	8	4	6	10	0	2	5	5	8	3	5	2	11	6	14	6
...ation versus not heparinoid added PRP %	-8	-35	-50	22	-64	34	8	-37	-50	22	-44	10	10	-39	-44	8	-35	-1
...iation versus Enoxaparine added PRP %	-9	58	76	3	-78	-14	-5	117	245	-10	-66	-27	-37	103	215	-34	-60	-35
WSD3093-Decasaccharides	1,64	1461	214,92	4,75	3,11	19	2,42	1386	140,45	7,85	5,43	24	3,71	1264	115,88	9,66	5,85	25
WSD3093-Decasaccharides	1,39	1461	209,28	4,75	3,37	23	2,68	1372	129,86	7,59	4,91	25	3,19	1385	126,06	9,66	6,47	23
Mean	1,51	1461,00	212,10	4,75	3,24	21,00	2,55	1379,00	135,16	7,72	5,17	24,50	3,45	1324,50	120,97	9,66	6,21	24,00
SD	0,18	0,00	3,99	0,00	0,18	2,83	0,18	9,90	7,49	0,18	0,37	0,71	0,37	85,56	7,20	0,00	0,37	1,41
CV %	12	0	2	0	6	13	7	1	6	2	7	3	11	6	6	0	6	6
...ation versus not heparinoid added PRP %	1	-10	-32	33	-61	31	13	-13	-35	33	-38	20	6	-16	-26	16	-25	3
...iation versus Enoxaparine added PRP %	0	121	139	12	-76	-16	0	201	348	-2	-62	-21	-39	182	314	-29	-54	-32
WSD3093-Dodecasaccharides	1,64	1594	155,7	6,64	3,9	28	2,68	1125	71	10,21	7,53	32	3,72	987	67,29	12,29	8,57	33
WSD3093-Dodecasaccharides	1,39	1522	169,91	5,28	3,99	23	2,42	1119	71,45	9,95	7,53	32	3,72	1050	71,93	11,25	7,53	31
Mean	1,52	1558,00	162,81	5,41	3,90	25,50	2,55	1122,00	71,23	10,08	7,53	32,00	3,72	978,50	64,61	11,77	8,05	32,00
SD	0,18	50,91	10,05	0,18	0,01	3,54	0,18	4,24	0,32	0,18	0,00	0,00	0,00	101,12	10,35	0,74	0,74	1,41
CV %	12	3	6	3	0	14	7	0	0	2	0	0	0	10	16	6	9	4
...ation versus not heparinoid added PRP %	1	-4	-48	52	-53	59	13	-29	-66	73	-9	56	14	-38	-60	42	-3	38
...iation versus Enoxaparine added PRP %	0	136	83	28	-71	2	0	145	136	28	-44	3	-34	108	121	-13	-41	-10
WSD3093-<Hexadecasaccharides	1,64	1548	189,24	5,02	3,38	23	2,68	1212	82,57	9,95	7,27	30	3,72	917	60,87	11,25	7,53	33
WSD3093-<Hexadecasaccharides	1,39	1556	187,75	5,02	3,63	22	2,42	1227	86,65	8,62	6,5	29	3,72	950	63,41	11,25	7,53	32
Mean	1,52	1552,00	185,50	5,02	3,51	22,50	2,55	1219,50	84,61	9,44	6,89	29,50	3,72	933,50	62,14	11,25	7,53	32,50
SD	0,18	5,66	3,19	0,00	0,18	0,71	0,18	10,61	2,88	0,73	0,54	0,71	0,00	23,33	1,80	0,00	0,00	0,71
CV %	12	0	2	0	5	3	7	1	3	8	8	2	0	2	3	0	0	2
...ation versus not heparinoid added PRP %	1	-4	-41	41	-58	41	13	-23	-59	62	-17	44	14	-41	-62	35	-9	40
...iation versus Enoxaparine added PRP %	0	135	109	19	-74	-10	0	166	181	20	-49	-5	-34	99	113	-17	-44	-8
...3093->=Hexadecasaccharides	1,75	351	35,81	5,5	3,75	27	5,24	141	7,7	19,18	13,94	37	ND	ND	ND	ND	#VALEUR!	ND
...093->=Hexadecasaccharides	1,75	306	39,63	5,25	3,5	17	7,05	272	13,53	23,32	16,27	37	ND	ND	ND	ND	#VALEUR!	ND
Mean	1,75	328,50	37,72	5,38	3,63	22,00	6,15	206,50	10,62	21,25	15,11	37,00	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#VALEUR!	#DIV/0!
SD	0,00	31,82	2,70	0,18	0,18	7,07	1,28	92,63	4,12	2,83	1,85	0,00	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#VALEUR!	#DIV/0!
CV %	0	10	7	3	5	32	21	45	39	14	11	0	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#VALEUR!	#DIV/0!
...iation versus not heparinoid added PRP %	17	-80	-88	51	-58	38	173	-87	-85	266	82	80	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#VALEUR!	#DIV/0!
...iation versus Enoxaparine added PRP %	16	-50	-58	27	-73	-12	141	-55	-65	170	11	19	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#VALEUR!	#DIV/0!
DIA2844-Hexasaccharides	1,88	1766	231,1	4,98	3,1	20	2,65	1927	218,77	7,05	4,4	21	4,2	1385	96,55	11,69	7,49	33
DIA2844-Hexasaccharides	1,62	1709	227,71	4,98	3,36	22	2,5	1523	225,47	6	3,5	19	3,95	1433	100,43	11,44	7,49	31
Mean	1,75	1732,50	229,41	4,98	3,23	21,00	2,58	1725,00	222,12	6,53	3,95	20,00	4,08	1409,00	98,49	11,57	7,49	32,00
SD	0,18	33,23	2,40	0,00	0,18	1,41	0,11	285,67	4,74	0,74	0,64	1,41	0,18	33,94	2,74	0,18	0,00	1,41
CV %	11	2	1	0	6	7	4	17	2	11	16	7	4	2	3	2	0	4
...iation versus not heparinoid added PRP %	17	7	-27	40	-61	31	14	9	6	12	-52	-2	25	-10	-40	39	-10	38
...iation versus Enoxaparine added PRP %	16	162	158	18	-76	-16	1	276	837	-17	-71	-35	-28	200	237	-15	-45	-10
DIA2844-Octasaccharides	1,9	1766	208,1	5,52	3,62	25	3,19	1650	134,91	9,15	5,96	28	5,26	1270	82,54	12,51	7,25	34
DIA2844-Octasaccharides	1,64	1776	223,28	5,26	3,62	22	2,94	1612	131,7	9,4	6,46	28	4,49	1499	123,84	10,7	6,21	29
Mean	1,77	1771,00	216,20	5,39	3,62	23,50	3,07	1631,00	133,28	9,28	6,21	28,00	4,88	1384,00	103,19	11,61	6,73	31,50
SD	0,18	7,07	10,03	0,18	0,00	2,12	0,18	26,87	2,20	0,18	0,35	0,00	0,54	161,22	29,20	1,28	0,74	3,54
CV %	10	0	5	3	0	9	6	2	2	2	6	0	11	12	28	11	11	11
...iation versus not heparinoid added PRP %	18	10	-31	51	-56	47	36	3	-39	69	-25	37	50	-12	-37	40	-19	35
...iation versus Enoxaparine added PRP %	17	168	143	27	-73	-5	28	255	342	18	-54	-10	-14	194	254	-14	-50	-11
DIA2844-Decasaccharides	1,75	1732	228,47	4,75	3	23	3	1402	103,7	8,5	5,5	32	4,25	1189	72,64	12,25	8	34
DIA2844-Decasaccharides	1,5	1578	252,49	4,5	3	17	2,75	1264	102,13	8	5,25	32	5	1273	82,41	12	7	34
Mean	1,63	1655,00	240,48	4,63	3,00	20,00	2,88	1333,00	102,92	8,25	5,38	32,00	4,63	1236,00	77,53	12,13	7,50	34,00
SD	0,18	108,89	16,98	0,18	0,00	4,24	0,18	97,58	1,11	0,35	0,18	0,00	0,53	52,33	6,91	0,18	0,71	0,00
CV %	11	7	7	4	0	21	6	7	1	4	3	0	11	4	9	1	9	0
...iation versus not heparinoid added PRP %	8	2	-23	30	-64	25	28	-18	-51	42	-35	56	42	-21	-52	46	-10	46
...iation versus Enoxaparine added PRP %	7	150	171	9	-73	-20	13	191	241	5	-66	3	-18	103	166	-11	-45	-4
DIA2844-Dodecasaccharides	2,13	1710	178,69	6,01	3,88	24	3,42	1544	91,86	10,92	7,5	32	5,23	1494	82,61	13,5	8,27	34
DIA2844-Dodecasaccharides	1,87	1787	191,93	5,49	3,62	24	3,17	1271	96,48	10,14	6,97	32	5,23	1141	76,53	12,47	7,24	32
Mean	2,00	1753,50	185,31	5,75	3,75	24,00	3,30	1407,50	94,17	10,53	7,24	32,00	5,23	1317,50	80,57	12,99	7,76	33,00
SD	0,18	61,52	9,36	0,37	0,18	0,00	0,18	183,04	3,27	0,55	0,37	0,00	0,00	249,61	2,98	0,73	0,73	1,41
CV %	9	4	5	6	5	0	5	14	3	5	5	0	0	19	4	6	9	4
...iation versus not heparinoid added PRP %	33	8	-41	61	-55	58	46	-11	-55	81	-13	56	61	-16	-51	56	-7	42
...iation versus Enoxaparine added PRP %	32	165	109	36	-72	-4	29	207	212	34	-47	3	-8	180	176	-4	-43	-7
DIA2844-<Hexadecasaccharides	1,87	1820	223,43	5,23	3,36	26	2,91	1580	121,58	9,37	6,46	29	4,46	1357	89,71	12,21	7,75	32
DIA2844-<Hexadecasaccharides	1,87	1785	226,53	4,97	3,1	22	3,17	1521	113,75	9,37	6,2	28	4,46	1705	123,21	11,43	6,97	32
Mean	1,87	1802,50	224,98	5,10	3,23	23,50	3,04	1550,50	117,67	9,37	6,33	28,50	4,46	1531,00	106,46	11,82	7,36	32,00
SD	0,00	24,75	2,19	0,18	0,18	2,12	0,18	41,72	5,54	0,00	0,18	0,71	0,00	246,07	23,69	0,55	0,55	0,00
CV %	0	1	1	4	6	9	6	3	5	0	3	2	0	16	22	5	7	0
...iation versus not heparinoid added PRP %	25	11	-28	43	-61	47	35	-2	-44	61	-24	39	37	-3	-35	42	-11	33
...iation versus Enoxaparine added PRP %	23	173	153	20	-76	-6	19	238	280	19	-53	-3	-21	226	265	-13	-46	-10
...DIA2844->=Hexadecasaccharides	3	177	16,96	8,5	5,5	25	17	N.D	7,79	33,5	16,5	N.D	N.D	N.D	N.D	N.D	N.D	N.D
...IA2844->=Hexadecasaccharides	1,75	96	8,66	7	5,25	24	16,25	N.D	9,12	36,5	20,25	N.D	N.D	N.D	N.D	N.D	N.D	N.D
Mean	2,38	136,50	12,81	7,75	5,38	24,50	16,63	#DIV/0!	8,46	35,00	18,38	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!
SD	0,88	57,28	5,87	1,06	0,18	0,71	0,63	#DIV/0!	0,94	2,12	2,65	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!
CV %	37	42	46	14	3	3	3	#DIV/0!	11	6	14	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!
...iation versus not heparinoid added PRP %	58	-62	-38	112	-35	53	636	#DIV/0!	-95	502	121	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!
...iation versus Enoxaparine added PRP %	57	-79	-85	93	-69	-2	552	#DIV/0!	-72	345	35	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!

Laboratoire LCL
RECHERCHE CLINIQUE

TABLE II

ETP variation % - Hemoliance Recombiplastin 1/100 diluted

		0,25 µg/mL	0,5 µg/mL	1 µg/mL	2,5 µg/mL	5 µg/mL	10 µg/mL
Enoxaparine		-9%	-10%	-5%	-17%	-29%	-71%
Hexasaccharides	WSD3093	-4%	-14%	-13%	-13%	-10%	-8%
	DIA2844	5%	-10%	-4%	3%	3%	9%
Octasaccharides	WSD3093	-1%	4%	-4%	-3%	-4%	-37%
	DIA2844	9%	2%	-3%	5%	2%	3%
Decasaccharides	WSD3093	-6%	-5%	-8%	-4%	-5%	-13%
	DIA2844	6%	5%	-1%	1%	-3%	-16%
Dodecasaccharides	WSD3093	-2%	-1%	6%	-13%	-13%	-29%
	DIA2844	0	7%	9%	2%	-5%	-11%
< Hexadecasaccharides	WSD3093	-8%	-3%	-2%	-8%	-10%	-23%
	DIA2844	6%	8%	5%	2%	8%	-2%
>= Hexadecasaccharides	WSD3093	11%	-1%	-9%	-24%	-59%	-87%
	DIA2844	-10%	-11%	-17%	-39%	-77%	uninterpretable

Laboratoire LCL RECHERCHE CLINIQUE

TABLE III

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	2,25	1593	204,07	6	3,75	21
	2,25	1621	209,86	6	3,75	21
	2,25	1614	210,32	5,75	3,5	20
	2,25	1517	211,37	5,5	3,25	20
Mean	**2,25**	**1586,25**	**208,91**	**5,81**	**3,56**	**20,50**
SD	0,00	47,68	3,28	0,24	0,24	0,58
CV %	0	3	2	4	7	3

Tested molecule	Heparinoïd concentration 0,5 µg/mL					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	2,25	1540	166,15	6,25	4	23
Enoxaparine	2,25	1832	166,4	6,25	4	26
Enoxaparine	2,25	1564	172,07	6	3,75	21
Enoxaparine	2,25	1531	171,23	6	3,75	22
Mean	**2,25**	**1616,75**	**168,96**	**6,13**	**3,88**	**23,00**
SD	0,00	144,17	3,12	0,14	0,14	2,16
CV %	0	9	2	2	4	9
Variation versus not heparinoïd added PRP %	0	2	-19	5	-33	12
WSD3093->=Hexadecasaccharides	2	1545	246,53	5	3	18
WSD3093->=Hexadecasaccharides	2	1694	243,52	5,25	3,25	24
WSD3093->=Hexadecasaccharides	2	1822	263,68	5	3	20
WSD3093->=Hexadecasaccharides	2	1520	246,67	5	3	18
Mean	**2,00**	**1645,25**	**250,10**	**5,06**	**3,06**	**20,00**
SD	0,00	140,66	9,17	0,13	0,13	2,83
CV %	0	9	4	2	4	14
Variation versus not heparinoïd added PRP %	-11	4	20	-13	-14	-2
Variation versus Enoxaparine added PRP %	-11	2	48	-17	-21	-13
DIA2844->=Hexadecasaccharides	2	1649	270,65	4,75	2,75	22
DIA2844->=Hexadecasaccharides	2	1450	257,59	4,5	2,5	16
DIA2844->=Hexadecasaccharides	2	1446	257,51	4,5	2,5	16
DIA2844->=Hexadecasaccharides	2	1409	255,83	4,5	2,5	16
Mean	**2,00**	**1488,50**	**260,40**	**4,56**	**2,56**	**17,50**
SD	0,00	108,58	6,88	0,13	0,13	3,00
CV %	0	7	3	3	5	17
Variation versus not heparinoïd added PRP %	-11	-6	25	-22	-28	-15
Variation versus Enoxaparine added PRP %	-11	-8	54	-26	-34	-24

Laboratoire LCL RECHERCHE CLINIQUE

TABLE III

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	2,25	1593	204,07	6	3,75	21
	2,25	1621	209,86	6	3,75	21
	2,25	1614	210,32	5,75	3,5	20
	2,25	1517	211,37	5,5	3,25	20
Mean	**2,25**	**1586,25**	**208,91**	**5,81**	**3,56**	**20,50**
SD	0,00	47,68	3,28	0,24	0,24	0,58
CV %	0	3	2	4	7	3

	Heparinoïd concentration 1 µg/mL					
Tested molecule	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	2,25	1647	150,66	6,75	4,5	25
Enoxaparine	2,5	1569	152,25	7	4,5	24
Enoxaparine	2,5	1515	154,52	6,5	4	24
Enoxaparine	2,25	1452	148,8	6,25	4	24
Mean	**2,38**	**1545,75**	**151,56**	**6,63**	**4,25**	**24,25**
SD	0,14	82,72	2,43	0,32	0,29	0,50
CV %	6	5	2	5	7	2
ation versus not heparinoïd added PRP %	6	-3	-27	14	-27	18
WSD3093->=Hexadecasaccharides	2	1676	229,27	5,5	3,5	27
WSD3093->=Hexadecasaccharides	2	1457	222,96	5,25	3,25	17
WSD3093->=Hexadecasaccharides	2,25	1573	234,08	5,25	3	20
WSD3093->=Hexadecasaccharides	2,25	1549	230,37	5,25	3	21
Mean	**2,13**	**1563,75**	**229,17**	**5,31**	**3,19**	**21,25**
SD	0,14	90,00	4,62	0,13	0,24	4,19
CV %	7	6	2	2	8	20
riation versus not heparinoïd added PRP %	-6	-1	10	-9	-11	4
ariation versus Enoxaparine added PRP %	-11	1	51	-20	-25	-12
DIA2844->=Hexadecasaccharides	2	1492	246,98	4,75	2,75	18
DIA2844->=Hexadecasaccharides	2	1436	239,65	4,75	2,75	18
DIA2844->=Hexadecasaccharides	2	1376	233,78	5	3	17
DIA2844->=Hexadecasaccharides	2	1350	233,04	4,75	2,75	17
Mean	**2,00**	**1413,50**	**238,36**	**4,81**	**2,81**	**17,50**
SD	0,00	63,53	6,46	0,13	0,13	0,58
CV %	0	4	3	3	4	3
riation versus not heparinoïd added PRP %	-11	-11	14	-17	-21	-15
ariation versus Enoxaparine added PRP %	-16	-9	57	-27	-34	-28

Laboratoire LCL RECHERCHE CLINIQUE

TABLE III

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	2,25	1593	204,07	6	3,75	21
	2,25	1621	209,86	6	3,75	21
	2,25	1614	210,32	5,75	3,5	20
	2,25	1517	211,37	5,5	3,25	20
Mean	**2,25**	**1586,25**	**208,91**	**5,81**	**3,56**	**20,50**
SD	0,00	47,68	3,28	0,24	0,24	0,58
CV %	0	3	2	4	7	3

Tested molecule	Heparinoïd concentration 1,6 µg/mL					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	2,5	1429	135,1	7	4,5	27
Enoxaparine	2,25	1521	146,31	6,75	4,5	24
Enoxaparine	2,25	1539	149,48	7	4,75	26
Enoxaparine	2,25	1436	145,91	6,5	4,25	26
Mean	**2,31**	**1481,25**	**144,20**	**6,81**	**4,50**	**25,75**
SD	0,13	56,84	6,27	0,24	0,20	1,26
CV %	5	4	4	4	5	5
riation versus not heparinoïd added PRP %	3	-7	-31	17	-23	26
WSD3093->=Hexadecasaccharides	2,25	1406	209,59	5,75	3,5	18
WSD3093->=Hexadecasaccharides	2,25	1390	204,43	5,5	3,25	20
WSD3093->=Hexadecasaccharides	2,25	1411	223,51	5,5	3,25	22
WSD3093->=Hexadecasaccharides	2,25	1528	214,03	5,25	3	21
Mean	**2,25**	**1433,75**	**212,89**	**5,50**	**3,25**	**20,25**
SD	0,00	63,47	8,09	0,20	0,20	1,71
CV %	0	4	4	4	6	8
Variation versus not heparinoïd added PRP %	0	-10	2	-5	-9	-1
Variation versus Enoxaparine added PRP %	-3	-3	48	-19	-28	-21
DIA2844->=Hexadecasaccharides	2,25	1336	195,66	5,5	3,25	20
DIA2844->=Hexadecasaccharides	2,25	1287	197,74	5,5	3,25	22
DIA2844->=Hexadecasaccharides	2,25	1257	192,32	5,25	3	20
DIA2844->=Hexadecasaccharides	2	1202	202,44	5	3	18
Mean	**2,19**	**1270,50**	**197,04**	**5,31**	**3,13**	**20,00**
SD	0,13	56,09	4,24	0,24	0,14	1,63
CV %	6	4	2	5	5	8
Variation versus not heparinoïd added PRP %	-3	-20	-6	-9	-12	-2
Variation versus Enoxaparine added PRP %	-5	-14	37	-22	-31	-22

Laboratoire LCL RECHERCHE CLINIQUE

TABLE III

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	2,25	1593	204,07	6	3,75	21
	2,25	1621	209,86	6	3,75	21
	2,25	1614	210,32	5,75	3,5	20
	2,25	1517	211,37	5,5	3,25	20
Mean	**2,25**	**1586,25**	**208,91**	**5,81**	**3,56**	**20,50**
SD	0,00	47,68	3,28	0,24	0,24	0,58
CV %	0	3	2	4	7	3

	Heparinoïd concentration 2,5 µg/mL					
Tested molecule	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	2,5	1368	126,74	7,75	5,25	30
Enoxaparine	2,5	1412	139,59	7,75	5,25	27
Enoxaparine	2,5	1476	128,9	7,75	5,25	27
Enoxaparine	2,5	1315	123,9	6,75	4,25	26
Mean	**2,50**	**1392,75**	**129,78**	**7,50**	**5,00**	**27,50**
SD	0,00	68,21	6,85	0,50	0,50	1,73
CV %	0	5	5	7	10	6
riation versus not heparinoïd added PRP %	11	-12	-38	29	-14	34
WSD3093->=Hexadecasaccharides	2,5	1339	166,65	6,75	4,25	24
WSD3093->=Hexadecasaccharides	2,5	1194	157,13	6,5	4	22
WSD3093->=Hexadecasaccharides	2,75	N.D	196,27	6,5	3,75	N.D
WSD3093->=Hexadecasaccharides	2,25	1239	174,58	6	3,75	18
Mean	**2,50**	**1257,33**	**173,66**	**6,44**	**3,94**	**21,33**
SD	0,20	74,22	16,68	0,31	0,24	3,06
CV %	8	6	10	5	6	14
Variation versus not heparinoïd added PRP %	11	-21	-17	11	11	4
Variation versus Enoxaparine added PRP %	0	-10	34	-14	-21	-22
DIA2844->=Hexadecasaccharides	2,5	1151	154,23	6,25	3,75	24
DIA2844->=Hexadecasaccharides	2,5	1071	143,32	6,25	3,75	21
DIA2844->=Hexadecasaccharides	2,5	1070	146,45	6	3,5	20
DIA2844->=Hexadecasaccharides	2,25	1010	146,22	5,75	3,5	20
Mean	**2,44**	**1075,50**	**147,56**	**6,06**	**3,63**	**21,25**
SD	0,13	57,85	4,67	0,24	0,14	1,89
CV %	5	5	3	4	4	9
Variation versus not heparinoïd added PRP %	8	-32	-29	4	2	4
Variation versus Enoxaparine added PRP %	-3	-23	14	-19	-28	-23

Laboratoire LCL RECHERCHE CLINIQUE

TABLE III

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	2,25	1593	204,07	6	3,75	21
	2,25	1621	209,86	6	3,75	21
	2,25	1614	210,32	5,75	3,5	20
	2,25	1517	211,37	5,5	3,25	20
Mean	**2,25**	**1586,25**	**208,91**	**5,81**	**3,56**	**20,50**
SD	0,00	47,68	3,28	0,24	0,24	0,58
CV %	0	3	2	4	7	3

Tested molecule	Heparinoïd concentration 4 µg/mL					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	2,75	1285	87,45	9,75	7	35
Enoxaparine	2,75	1219	99,24	8,5	5,75	28
Enoxaparine	2,75	1244	90,37	9	6,25	32
Enoxaparine	2,75	1159	91,33	8,25	5,5	30
Mean	**2,75**	**1226,75**	**92,10**	**8,88**	**6,13**	**31,25**
SD	0,00	52,73	5,04	0,66	0,66	2,99
CV %	0	4	5	7	11	10
Variation versus not heparinoïd added PRP %	22	-23	-56	53	5	52
WSD3093->=Hexadecasaccharides	2,75	865	88,19	8,5	5,75	24
WSD3093->=Hexadecasaccharides	2,5	843	89,8	8	5,5	24
WSD3093->=Hexadecasaccharides	2,5	890	96,74	8	5,5	23
WSD3093->=Hexadecasaccharides	2,75	911	103,87	7,75	5	24
Mean	**2,63**	**877,25**	**94,65**	**8,06**	**5,44**	**23,75**
SD	0,14	29,58	7,18	0,31	0,31	0,50
CV %	5	3	8	4	6	2
Variation versus not heparinoïd added PRP %	17	-45	-55	39	53	16
Variation versus Enoxaparine added PRP %	-5	-28	3	-9	-11	-24
DIA2844->=Hexadecasaccharides	2,75	714	74,37	7,5	4,75	24
DIA2844->=Hexadecasaccharides	2,5	714	72,08	7,5	5	26
DIA2844->=Hexadecasaccharides	2,75	680	78,49	7	4,25	22
DIA2844->=Hexadecasaccharides	2,75	639	64,3	7,5	4,75	26
Mean	**2,69**	**686,75**	**72,31**	**7,38**	**4,69**	**24,50**
SD	0,13	35,64	5,96	0,25	0,31	1,91
CV %	5	5	8	3	7	8
Variation versus not heparinoïd added PRP %	19	-57	-65	27	32	20
Variation versus Enoxaparine added PRP %	-2	-44	-21	-17	-23	-22

Laboratoire LCL RECHERCHE CLINIQUE

TABLE III

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	2,25	1593	204,07	6	3,75	21
	2,25	1621	209,86	6	3,75	21
	2,25	1614	210,32	5,75	3,5	20
	2,25	1517	211,37	5,5	3,25	20
Mean	**2,25**	**1586,25**	**208,91**	**5,81**	**3,56**	**20,50**
SD	0,00	47,68	3,28	0,24	0,24	0,58
CV %	0	3	2	4	7	3

Tested molecule	Heparinoïd concentration 5 µg/mL					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	3	1048	72,44	9,75	6,75	33
Enoxaparine	3,25	1051	74,65	9,75	6,5	32
Enoxaparine	3	873	66,73	9,5	6,5	32
Enoxaparine	3	968	62,41	10,25	7,25	34
Mean	**3,06**	**985,00**	**69,06**	**9,81**	**6,75**	**32,75**
SD	0,13	83,98	5,55	0,31	0,35	0,96
CV %	4	9	8	3	5	3
ation versus not heparinoïd added PRP %	36	-38	-67	69	16	60
WSD3093->=Hexadecasaccharides	3	678	56,92	10	7	26
WSD3093->=Hexadecasaccharides	2,75	624	55,74	9,25	6,5	29
WSD3093->=Hexadecasaccharides	3	695	57,71	9,5	6,5	27
WSD3093->=Hexadecasaccharides	3	688	55,18	9,75	6,75	28
Mean	**2,94**	**671,25**	**56,39**	**9,63**	**6,69**	**27,50**
SD	0,13	32,26	1,14	0,32	0,24	1,29
CV %	4	5	2	3	4	5
ation versus not heparinoïd added PRP %	31	-58	-73	66	88	34
iation versus Enoxaparine added PRP %	-4	-32	-18	-2	-1	-16
DIA2844->=Hexadecasaccharides	3	535	46,99	8,25	5,25	29
DIA2844->=Hexadecasaccharides	3	515	44,31	8,25	5,25	30
DIA2844->=Hexadecasaccharides	3,25	501	41,78	8,75	5,5	31
DIA2844->=Hexadecasaccharides	2,75	505	44,93	7,75	5	28
Mean	**3,00**	**514,00**	**44,50**	**8,25**	**5,25**	**29,50**
SD	0,20	15,19	2,15	0,41	0,20	1,29
CV %	7	3	5	5	4	4
ation versus not heparinoïd added PRP %	33	-68	-79	42	47	44
iation versus Enoxaparine added PRP %	-2	-48	-36	-16	-22	-10

Laboratoire LCL RECHERCHE CLINIQUE

TABLE III

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	2,25	1593	204,07	6	3,75	21
	2,25	1621	209,86	6	3,75	21
	2,25	1614	210,32	5,75	3,5	20
	2,25	1517	211,37	5,5	3,25	20
Mean	**2,25**	**1586,25**	**208,91**	**5,81**	**3,56**	**20,50**
SD	0,00	47,68	3,28	0,24	0,24	0,58
CV %	0	3	2	4	7	3

Tested molecule	Heparinoïd concentration 6,25 µg/mL					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	3	737	43,43	11,25	8,25	34
Enoxaparine	3	796	50,36	10,25	7,25	34
Enoxaparine	3	832	53,97	9,75	6,75	34
Enoxaparine	3	806	48,54	11	8	35
Mean	**3,00**	**792,75**	**49,08**	**10,56**	**7,56**	**34,25**
SD	0,00	40,14	4,39	0,69	0,69	0,50
CV %	0	5	9	7	9	1
tion versus not heparinoïd added PRP %	33	-50	-77	82	30	67
WSD3093->=Hexadecasaccharides	2,75	492	33,99	10,25	7,5	30
WSD3093->=Hexadecasaccharides	2,75	465	32,33	10,25	7,5	31
WSD3093->=Hexadecasaccharides	3	532	37,81	10,25	7,25	30
WSD3093->=Hexadecasaccharides	2,75	489	34,72	10,25	7,5	30
Mean	**2,81**	**494,50**	**34,71**	**10,25**	**7,44**	**30,25**
SD	0,13	27,77	2,29	0,00	0,13	0,50
CV %	4	6	7	0	2	2
ariation versus not heparinoïd added PRP %	25	-69	-83	76	109	48
/ariation versus Enoxaparine added PRP %	-6	-38	-29	-3	-2	-12
DIA2844->=Hexadecasaccharides	3,25	353	26,52	10,75	7,5	29
DIA2844->=Hexadecasaccharides	3	320	23,01	9,25	6,25	32
DIA2844->=Hexadecasaccharides	3	347	25,66	9,75	6,75	30
DIA2844->=Hexadecasaccharides	3	344	25,51	9,5	6,5	31
Mean	**3,06**	**341,00**	**25,18**	**9,81**	**6,75**	**30,50**
SD	0,13	14,49	1,51	0,66	0,54	1,29
CV %	4	4	6	7	8	4
ariation versus not heparinoïd added PRP %	36	-79	-88	69	89	49
/ariation versus Enoxaparine added PRP %	2	-57	-49	-7	-11	-11

Laboratoire LCL RECHERCHE CLINIQUE

TABLE III

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	2,25	1593	204,07	6	3,75	21
	2,25	1621	209,86	6	3,75	21
	2,25	1614	210,32	5,75	3,5	20
	2,25	1517	211,37	5,5	3,25	20
Mean	**2,25**	**1586,25**	**208,91**	**5,81**	**3,56**	**20,50**
SD	0,00	47,68	3,28	0,24	0,24	0,58
CV %	0	3	2	4	7	3

	Heparinoïd concentration 8 µg/mL					
Tested molecule	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	3,75	615	37,03	11,75	8	35
Enoxaparine	3,25	483	29,1	11,5	8,25	33
Enoxaparine	3,5	520	29,52	12	8,5	34
Enoxaparine	3,75	685	37,82	11,25	7,5	32
Mean	**3,56**	**575,75**	**33,37**	**11,63**	**8,06**	**33,50**
SD	0,24	91,63	4,70	0,32	0,43	1,29
CV %	7	16	14	3	5	4
riation versus not heparinoïd added PRP %	58	-64	-84	100	39	63
WSD3093->=Hexadecasaccharides	3,5	223	14,74	11,75	8,25	31
WSD3093->=Hexadecasaccharides	3	282	17,76	10,25	7,25	31
WSD3093->=Hexadecasaccharides	3	295	17,89	10,5	7,5	32
WSD3093->=Hexadecasaccharides	3	269	17,26	10	7	32
Mean	**3,13**	**267,25**	**16,91**	**10,63**	**7,50**	**31,50**
SD	0,25	31,35	1,47	0,78	0,54	0,58
CV %	8	12	9	7	7	2
Variation versus not heparinoïd added PRP %	39	-83	-92	83	111	54
Variation versus Enoxaparine added PRP %	-12	-54	-49	-9	-7	-6
DIA2844->=Hexadecasaccharides	3,25	204	14,41	10,25	7	30
DIA2844->=Hexadecasaccharides	3,75	189	13,68	10,25	6,5	29
DIA2844->=Hexadecasaccharides	3	168	11,68	10,5	7,5	29
DIA2844->=Hexadecasaccharides	4	235	16,74	11,25	7,25	32
Mean	**3,50**	**199,00**	**14,13**	**10,56**	**7,06**	**30,00**
SD	0,46	28,18	2,09	0,47	0,43	1,41
CV %	13	14	15	4	6	5
Variation versus not heparinoïd added PRP %	56	-87	-93	82	98	46
Variation versus Enoxaparine added PRP %	-2	-65	-58	-9	-12	-10

Laboratoire LCL RECHERCHE CLINIQUE

TABLE III

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	2,25	1593	204,07	6	3,75	21
	2,25	1621	209,86	6	3,75	21
	2,25	1614	210,32	5,75	3,5	20
	2,25	1517	211,37	5,5	3,25	20
Mean	**2,25**	**1586,25**	**208,91**	**5,81**	**3,56**	**20,50**
SD	0,00	47,68	3,28	0,24	0,24	0,58
CV %	0	3	2	4	7	3

Tested molecule	Heparinoïd concentration 9 µg/mL					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	4,25	382	23,24	14,75	10,5	26
Enoxaparine	4	353	20,3	13,75	9,75	33
Enoxaparine	3,75	391	22,48	12,25	8,5	33
Enoxaparine	3,75	390	22,9	11,75	8	33
Mean	**3,94**	**379,00**	**22,23**	**13,13**	**9,19**	**31,25**
SD	0,24	17,80	1,32	1,38	1,14	3,50
CV %	6	5	6	10	12	11
riation versus not heparinoïd added PRP %	75	-76	-89	126	58	52
WSD3093->=Hexadecasaccharides	3,25	223	13,65	11,25	8	32
WSD3093->=Hexadecasaccharides	3,25	184	10,64	10,75	7,5	32
WSD3093->=Hexadecasaccharides	3	206	12,47	11,25	8,25	32
WSD3093->=Hexadecasaccharides	3	187	11,8	10,5	7,5	30
Mean	**3,13**	**200,00**	**12,14**	**10,94**	**7,81**	**31,50**
SD	0,14	18,17	1,26	0,38	0,38	1,00
CV %	5	9	10	3	5	3
Variation versus not heparinoïd added PRP %	39	-87	-94	88	119	54
Variation versus Enoxaparine added PRP %	-21	-47	-45	-17	-15	1
DIA2844->=Hexadecasaccharides	4	144	8,86	13,5	9,5	32
DIA2844->=Hexadecasaccharides	4,75	148	9,91	12,5	7,75	30
DIA2844->=Hexadecasaccharides	4	140	9,82	11,5	7,5	30
DIA2844->=Hexadecasaccharides	2,5	124	8,36	11,5	9	30
Mean	**3,81**	**139,00**	**9,24**	**12,25**	**8,44**	**30,50**
SD	0,94	10,52	0,75	0,96	0,97	1,00
CV %	25	8	8	8	11	3
Variation versus not heparinoïd added PRP %	69	-91	-96	111	137	49
Variation versus Enoxaparine added PRP %	-3	-63	-58	-7	-8	-2

Laboratoire LCL RECHERCHE CLINIQUE

TABLE III

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	2,25	1593	204,07	6	3,75	21
	2,25	1621	209,86	6	3,75	21
	2,25	1614	210,32	5,75	3,5	20
	2,25	1517	211,37	5,5	3,25	20
Mean	**2,25**	**1586,25**	**208,91**	**5,81**	**3,56**	**20,50**
SD	0,00	47,68	3,28	0,24	0,24	0,58
CV %	0	3	2	4	7	3

Tested molecule	Heparinoïd concentration 10 µg/mL					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	4,75	353	21	13,75	9	33
Enoxaparine	4,5	376	22,9	13,25	8,75	33
Enoxaparine	4,75	273	16,57	12,75	8	31
Enoxaparine	3,5	215	11,98	13	9,5	32
Mean	**4,38**	**304,25**	**18,11**	**13,19**	**8,81**	**32,25**
SD	0,60	74,09	4,87	0,43	0,63	0,96
CV %	14	24	27	3	7	3
Variation versus not heparinoïd added PRP %	94	-81	-91	127	52	57
WSD3093->=Hexadecasaccharides	3,75	142	8,73	11,5	7,75	31
WSD3093->=Hexadecasaccharides	4,5	99	5,28	15	10,5	33
WSD3093->=Hexadecasaccharides	3	109	6,7	11,25	8,25	31
WSD3093->=Hexadecasaccharides	3,25	120	6,35	11,75	8,5	30
Mean	**3,63**	**117,50**	**6,77**	**12,38**	**8,75**	**31,25**
SD	0,66	18,45	1,44	1,76	1,21	1,26
CV %	18	16	21	14	14	4
Variation versus not heparinoïd added PRP %	61	-93	-97	113	146	52
Variation versus Enoxaparine added PRP %	-17	-61	-63	-6	-1	-3
DIA2844->=Hexadecasaccharides	4,5	157	8,33	18	13,5	34
DIA2844->=Hexadecasaccharides	5	142	8,23	17,25	12,25	34
DIA2844->=Hexadecasaccharides	4,75	138	7,4	16	11,25	33
DIA2844->=Hexadecasaccharides	3	93	5,53	13	10	30
Mean	**4,31**	**132,50**	**7,37**	**16,06**	**11,75**	**32,75**
SD	0,90	27,57	1,30	2,20	1,49	1,89
CV %	21	21	18	14	13	6
Variation versus not heparinoïd added PRP %	92	-92	-96	176	230	60
Variation versus Enoxaparine added PRP %	-1	-56	-59	22	33	2

Laboratoire LCL RECHERCHE CLINIQUE

TABLE IV

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	1,75	1322	182,78	4,5	2,75	27
	1,75	1300	203,28	4,25	2,5	17
	1,75	1278	197,72	4,25	2,5	17
	1,75	1140	188,99	4	2,25	17
Mean	**1,75**	**1260,00**	**193,19**	**4,25**	**2,50**	**19,50**
SD	0,00	81,99	9,10	0,20	0,20	5,00
CV %	0	7	5	5	8	26

	Heparinoïd concentration 0,5 µg/mL					
Tested molecule	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	1,75	1258	199,92	4,25	2,5	16
Enoxaparine	1,75	1308	196,03	4,25	2,5	19
Enoxaparine	1,75	1206	185,78	4,5	2,75	17
Mean	**1,75**	**1257,33**	**193,91**	**4,33**	**2,58**	**17,33**
SD	0,00	51,00	7,30	0,14	0,14	1,53
CV %	0	4	4	3	6	9
riation versus not heparinoïd added PRP %	0	0	0	2	-39	-11
WSD3093->=Hexadecasaccharides	1,75	1511	237	4,25	2,5	26
WSD3093->=Hexadecasaccharides	1,75	1332	225,02	4,25	2,5	17
WSD3093->=Hexadecasaccharides	1,75	1367	231,27	4,25	2,5	20
Mean	**1,75**	**1403,33**	**231,10**	**4,25**	**2,50**	**21,00**
SD	0,00	94,87	5,99	0,00	0,00	4,58
CV %	0	7	3	0	0	22
Variation versus not heparinoïd added PRP %	0	11	20	0	0	8
Variation versus Enoxaparine added PRP %	0	12	19	-2	-3	21
DIA2844->=Hexadecasaccharides	1,75	1430	242,97	4,25	2,5	16
DIA2844->=Hexadecasaccharides	1,75	1413	236,18	4,25	2,5	19
DIA2844->=Hexadecasaccharides	1,75	1396	253,04	4,25	2,5	15
Mean	**1,75**	**1413,00**	**244,06**	**4,25**	**2,50**	**16,67**
SD	0,00	17,00	8,48	0,00	0,00	2,08
CV %	0	1	3	0	0	12
Variation versus not heparinoïd added PRP %	0	12	26	0	0	-15
Variation versus Enoxaparine added PRP %	0	12	26	-2	-3	-4

Laboratoire LCL RECHERCHE CLINIQUE

TABLE IV

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	1,75	1322	182,78	4,5	2,75	27
	1,75	1300	203,28	4,25	2,5	17
	1,75	1278	197,72	4,25	2,5	17
	1,75	1140	188,99	4	2,25	17
Mean	**1,75**	**1260,00**	**193,19**	**4,25**	**2,50**	**19,50**
SD	0,00	81,99	9,10	0,20	0,20	5,00
CV %	0	7	5	5	8	26

	Heparinoïd concentration 1 µg/mL					
Tested molecule	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	1,75	1244	185,15	4,25	2,5	19
Enoxaparine	1,75	1195	187,74	4,5	2,75	18
Enoxaparine	1,75	1448	197,97	4,5	2,75	24
Mean	**1,75**	**1295,67**	**190,29**	**4,42**	**2,67**	**20,33**
SD	0,00	134,18	6,78	0,14	0,14	3,21
CV %	0	10	4	3	5	16
iation versus not heparinoïd added PRP %	0	3	-2	4	-37	4
WSD3093->=Hexadecasaccharides	1,75	1338	224,83	4,25	2,5	19
WSD3093->=Hexadecasaccharides	1,75	1331	217,57	4,5	2,75	21
WSD3093->=Hexadecasaccharides	1,75	1313	222,82	4,5	2,75	20
Mean	**1,75**	**1327,33**	**221,74**	**4,42**	**2,67**	**20,00**
SD	0,00	12,90	3,75	0,14	0,14	1,00
CV %	0	1	2	3	5	5
/ariation versus not heparinoïd added PRP %	0	5	15	4	7	3
Variation versus Enoxaparine added PRP %	0	2	17	0	0	-2
DIA2844->=Hexadecasaccharides	1,75	1387	232,59	4,5	2,75	18
DIA2844->=Hexadecasaccharides	1,75	1292	219,46	4,5	2,75	17
DIA2844->=Hexadecasaccharides	1,75	1306	212,89	4,5	2,75	24
Mean	**1,75**	**1328,33**	**221,65**	**4,50**	**2,75**	**19,67**
SD	0,00	51,29	10,03	0,00	0,00	3,79
CV %	0	4	5	0	0	19
/ariation versus not heparinoïd added PRP %	0	5	15	6	10	1
Variation versus Enoxaparine added PRP %	0	3	16	2	3	-3

Laboratoire LCL RECHERCHE CLINIQUE

TABLE IV

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	1,75	1322	182,78	4,5	2,75	27
	1,75	1300	203,28	4,25	2,5	17
	1,75	1278	197,72	4,25	2,5	17
	1,75	1140	188,99	4	2,25	17
Mean	**1,75**	**1260,00**	**193,19**	**4,25**	**2,50**	**19,50**
SD	0,00	81,99	9,10	0,20	0,20	5,00
CV %	0	7	5	5	8	26

	Heparinoïd concentration 1,6 µg/mL					
Tested molecule	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	2	1185	169,39	4,75	2,75	19
Enoxaparine	2	ND	186,49	4,75	2,75	ND
Enoxaparine	1,75	1255	177,46	4,5	2,75	25
Mean	**1,92**	**1220,00**	**177,78**	**4,67**	**2,75**	**22,00**
SD	0,14	49,50	8,55	0,14	0,00	4,24
CV %	8	4	5	3	0	19
riation versus not heparinoïd added PRP %	10	-3	-8	10	-35	13
WSD3093->=Hexadecasaccharides	1,75	1229	202,04	4,75	3	24
WSD3093->=Hexadecasaccharides	2	1213	198,39	4,75	2,75	22
WSD3093->=Hexadecasaccharides	2	1233	199,33	4,5	2,5	21
Mean	**1,92**	**1225,00**	**199,92**	**4,67**	**2,75**	**22,33**
SD	0,14	10,58	1,90	0,14	0,25	1,53
CV %	8	1	1	3	9	7
Variation versus not heparinoïd added PRP %	10	-3	3	10	10	15
Variation versus Enoxaparine added PRP %	0	0	12	0	0	2
DIA2844->=Hexadecasaccharides	2	1306	196,43	5	3	24
DIA2844->=Hexadecasaccharides	2	1153	186,35	4,75	2,75	25
DIA2844->=Hexadecasaccharides	2	1242	182,26	5	3	26
Mean	**2,00**	**1233,67**	**188,35**	**4,92**	**2,92**	**25,00**
SD	0,00	76,84	7,29	0,14	0,14	1,00
CV %	0	6	4	3	5	4
Variation versus not heparinoïd added PRP %	14	-2	-3	16	17	28
Variation versus Enoxaparine added PRP %	4	1	6	5	6	14

Laboratoire LCL RECHERCHE CLINIQUE

TABLE IV

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	1,75	1322	182,78	4,5	2,75	27
	1,75	1300	203,28	4,25	2,5	17
	1,75	1278	197,72	4,25	2,5	17
	1,75	1140	188,99	4	2,25	17
Mean	**1,75**	**1260,00**	**193,19**	**4,25**	**2,50**	**19,50**
SD	0,00	81,99	9,10	0,20	0,20	5,00
CV %	0	7	5	5	8	26

	Heparinoïd concentration 2,5 µg/mL					
Tested molecule	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	2	1205	156,13	5,25	3,25	20
Enoxaparine	2,25	1183	150,26	5,5	3,25	21
Enoxaparine	2	1089	147,19	5	3	20
Mean	**2,08**	**1159,00**	**151,19**	**5,25**	**3,17**	**20,33**
SD	0,14	61,61	4,54	0,25	0,14	0,58
CV %	7	5	3	5	5	3
riation versus not heparinoïd added PRP %	19	-8	-22	24	-25	4
WSD3093->=Hexadecasaccharides	2	1091	164,66	5,25	3,25	22
WSD3093->=Hexadecasaccharides	2	1069	158,65	5,5	3,5	20
WSD3093->=Hexadecasaccharides	2	1070	163,16	5,25	3,25	22
Mean	**2,00**	**1076,67**	**162,16**	**5,33**	**3,33**	**21,33**
SD	0,00	12,42	3,13	0,14	0,14	1,15
CV %	0	1	2	3	4	5
Variation versus not heparinoïd added PRP %	14	-15	-16	25	33	9
Variation versus Enoxaparine added PRP %	-4	-7	7	2	5	5
DIA2844->=Hexadecasaccharides	2,25	970	141,78	5,75	3,5	22
DIA2844->=Hexadecasaccharides	2,25	964	139,78	5,5	3,25	25
DIA2844->=Hexadecasaccharides	2	912	133,24	5,5	3,5	21
Mean	**2,17**	**948,67**	**138,27**	**5,58**	**3,42**	**22,67**
SD	0,14	31,90	4,47	0,14	0,14	2,08
CV %	7	3	3	3	4	9
Variation versus not heparinoïd added PRP %	24	-25	-28	31	37	16
Variation versus Enoxaparine added PRP %	4	-18	-9	6	8	11

Laboratoire LCL RECHERCHE CLINIQUE

TABLE IV

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	1,75	1322	182,78	4,5	2,75	27
	1,75	1300	203,28	4,25	2,5	17
	1,75	1278	197,72	4,25	2,5	17
	1,75	1140	188,99	4	2,25	17
Mean	**1,75**	**1260,00**	**193,19**	**4,25**	**2,50**	**19,50**
SD	0,00	81,99	9,10	0,20	0,20	5,00
CV %	0	7	5	5	8	26

Tested molecule	Heparinoïd concentration 4 µg/mL					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	2,25	1031	117,98	5,75	3,5	24
Enoxaparine	2,25	1063	131,14	5,75	3,5	20
Enoxaparine	2,5	1047	116,58	6	3,5	23
Mean	**2,33**	**1047,00**	**121,90**	**5,83**	**3,50**	**22,33**
SD	0,14	16,00	8,03	0,14	0,00	2,08
CV %	6	2	7	2	0	9
'iation versus not heparinoïd added PRP %	33	-17	-37	37	-18	15
WSD3093->=Hexadecasaccharides	2,25	720	94,69	6,5	4,25	24
WSD3093->=Hexadecasaccharides	2,5	712	94,17	6,5	4	20
WSD3093->=Hexadecasaccharides	2,25	698	93,22	6,25	4	21
Mean	**2,33**	**710,00**	**94,03**	**6,42**	**4,08**	**21,67**
SD	0,14	11,14	0,75	0,14	0,14	2,08
CV %	6	2	1	2	4	10
Variation versus not heparinoïd added PRP %	33	-44	-51	51	63	11
Variation versus Enoxaparine added PRP %	0	-32	-23	10	17	-3
DIA2844->=Hexadecasaccharides	2,5	624	78,73	7	4,5	18
DIA2844->=Hexadecasaccharides	2,5	559	68,62	7	4,5	20
DIA2844->=Hexadecasaccharides	2,5	584	65,13	7	4,5	24
Mean	**2,50**	**589,00**	**70,83**	**7,00**	**4,50**	**20,67**
SD	0,00	32,79	7,06	0,00	0,00	3,06
CV %	0	6	10	0	0	15
Variation versus not heparinoïd added PRP %	43	-53	-63	65	80	6
Variation versus Enoxaparine added PRP %	7	-44	-42	20	29	-7

Laboratoire LCL RECHERCHE CLINIQUE

TABLE IV

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	1,75	1322	182,78	4,5	2,75	27
	1,75	1300	203,28	4,25	2,5	17
	1,75	1278	197,72	4,25	2,5	17
	1,75	1140	188,99	4	2,25	17
Mean	**1,75**	**1260,00**	**193,19**	**4,25**	**2,50**	**19,50**
SD	0,00	81,99	9,10	0,20	0,20	5,00
CV %	0	7	5	5	8	26

Tested molecule	Heparinoïd concentration 5 µg/mL					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	2,5	1006	103,76	6,75	4,25	24
Enoxaparine	2,5	844	102,14	6,25	3,75	15
Enoxaparine	2,5	963	109,58	6	3,5	22
Mean	**2,50**	**937,67**	**105,16**	**6,33**	**3,83**	**20,33**
SD	0,00	83,92	3,91	0,38	0,38	4,73
CV %	0	9	4	6	10	23
tion versus not heparinoïd added PRP %	43	-26	-46	49	-10	4
WSD3093->=Hexadecasaccharides	2,5	578	71,84	6,5	4	22
WSD3093->=Hexadecasaccharides	2,25	543	71,22	6,5	4,25	18
WSD3093->=Hexadecasaccharides	2,5	558	72,21	6,25	3,75	20
Mean	**2,42**	**559,67**	**71,76**	**6,42**	**4,00**	**20,00**
SD	0,14	17,56	0,50	0,14	0,25	2,00
CV %	6	3	1	2	6	10
riation versus not heparinoïd added PRP %	38	-56	-63	51	60	3
ariation versus Enoxaparine added PRP %	-3	-40	-32	1	4	-2
DIA2844->=Hexadecasaccharides	2,5	458	49,88	7,5	5	22
DIA2844->=Hexadecasaccharides	2,5	426	45,08	7,75	5,25	22
DIA2844->=Hexadecasaccharides	2,5	420	46,37	7,25	4,75	22
Mean	**2,50**	**434,67**	**47,11**	**7,50**	**5,00**	**22,00**
SD	0,00	20,43	2,48	0,25	0,25	0,00
CV %	0	5	5	3	5	0
riation versus not heparinoïd added PRP %	43	-66	-76	76	100	13
ariation versus Enoxaparine added PRP %	0	-54	-55	18	30	8

Laboratoire LCL RECHERCHE CLINIQUE

TABLE IV

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	1,75	1322	182,78	4,5	2,75	27
	1,75	1300	203,28	4,25	2,5	17
	1,75	1278	197,72	4,25	2,5	17
	1,75	1140	188,99	4	2,25	17
Mean	**1,75**	**1260,00**	**193,19**	**4,25**	**2,50**	**19,50**
SD	0,00	81,99	9,10	0,20	0,20	5,00
CV %	0	7	5	5	8	26

	Heparinoïd concentration 6,25 µg/mL					
Tested molecule	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	2,75	853	73,94	7,25	4,5	30
Enoxaparine	2,75	709	66,4	7	4,25	26
Enoxaparine	3	ND	81,98	7,5	4,5	ND
Mean	**2,83**	**781,00**	**74,11**	**7,25**	**4,42**	**28,00**
SD	0,14	101,82	7,79	0,25	0,14	2,83
CV %	5	13	11	3	3	10
iation versus not heparinoïd added PRP %	62	-38	-62	71	4	44
WSD3093->=Hexadecasaccharides	2,75	492	51,2	7,75	5	24
WSD3093->=Hexadecasaccharides	2,5	443	47,31	7,5	5	22
WSD3093->=Hexadecasaccharides	2,75	476	52,88	7	4,25	20
Mean	**2,67**	**470,33**	**50,46**	**7,42**	**4,75**	**22,00**
SD	0,14	24,99	2,86	0,38	0,43	2,00
CV %	5	5	6	5	9	9
Variation versus not heparinoïd added PRP %	52	-63	-74	75	90	13
Variation versus Enoxaparine added PRP %	-6	-40	-32	2	8	-21
DIA2844->=Hexadecasaccharides	3	355	30,8	8,5	5,5	25
DIA2844->=Hexadecasaccharides	3	351	30,37	8,5	5,5	27
DIA2844->=Hexadecasaccharides	2,75	328	26,37	8,75	6	27
Mean	**2,92**	**344,67**	**29,18**	**8,58**	**5,67**	**26,33**
SD	0,14	14,57	2,44	0,14	0,29	1,15
CV %	5	4	8	2	5	4
Variation versus not heparinoïd added PRP %	67	-73	-85	102	127	35
Variation versus Enoxaparine added PRP %	3	-56	-61	18	28	-6

Laboratoire LCL RECHERCHE CLINIQUE

TABLE IV

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	1,75	1322	182,78	4,5	2,75	27
	1,75	1300	203,28	4,25	2,5	17
	1,75	1278	197,72	4,25	2,5	17
	1,75	1140	188,99	4	2,25	17
Mean	**1,75**	**1260,00**	**193,19**	**4,25**	**2,50**	**19,50**
SD	0,00	81,99	9,10	0,20	0,20	5,00
CV %	0	7	5	5	8	26

	Heparinoïd concentration 8 µg/mL					
Tested molecule	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	3	563	48,52	8	5	28
Enoxaparine	3	713	52,78	8,25	5,25	34
Enoxaparine	3	642	49,26	8	5	31
Mean	**3,00**	**639,33**	**50,19**	**8,08**	**5,08**	**31,00**
SD	0,00	75,04	2,28	0,14	0,14	3,00
CV %	0	12	5	2	3	10
riation versus not heparinoïd added PRP %	71	-49	-74	90	20	59
WSD3093->=Hexadecasaccharides	2,75	329	26,84	7,75	5	27
WSD3093->=Hexadecasaccharides	2,75	339	27,51	8,75	6	28
WSD3093->=Hexadecasaccharides	3	365	27,82	8,5	5,5	31
Mean	**2,83**	**344,33**	**27,39**	**8,33**	**5,50**	**28,67**
SD	0,14	18,58	0,50	0,52	0,50	2,08
CV %	5	5	2	6	9	7
Variation versus not heparinoïd added PRP %	62	-73	-86	96	120	47
Variation versus Enoxaparine added PRP %	-6	-46	-45	3	8	-8
DIA2844->=Hexadecasaccharides	3	244	17,15	9,5	6,5	32
DIA2844->=Hexadecasaccharides	3,25	239	16,74	10	6,75	30
DIA2844->=Hexadecasaccharides	3,25	225	16,45	9,25	6	29
Mean	**3,17**	**236,00**	**16,78**	**9,58**	**6,42**	**30,33**
SD	0,14	9,85	0,35	0,38	0,38	1,53
CV %	5	4	2	4	6	5
Variation versus not heparinoïd added PRP %	81	-31	-91	125	157	56
Variation versus Enoxaparine added PRP %	6	-63	-67	19	26	-2

Laboratoire LCL RECHERCHE CLINIQUE

TABLE IV

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	1,75	1322	182,78	4,5	2,75	27
	1,75	1300	203,28	4,25	2,5	17
	1,75	1278	197,72	4,25	2,5	17
	1,75	1140	188,99	4	2,25	17
Mean	**1,75**	**1260,00**	**193,19**	**4,25**	**2,50**	**19,50**
SD	0,00	81,99	9,10	0,20	0,20	5,00
CV %	0	7	5	5	8	26

	Heparinoïd concentration 9 µg/mL					
Tested molecule	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	3,25	540	34,11	9,5	6,25	34
Enoxaparine	3,25	584	38,2	8,5	5,25	33
Enoxaparine	3,25	508	35,44	8,5	5,25	32
Mean	**3,25**	**544,00**	**35,92**	**8,83**	**5,58**	**33,00**
SD	0,00	38,16	2,09	0,58	0,58	1,00
CV %	0	7	6	7	10	3
Variation versus not heparinoïd added PRP %	86	-57	-81	108	31	69
WSD3093->=Hexadecasaccharides	3,25	299	23,08	7,75	4,5	29
WSD3093->=Hexadecasaccharides	3	278	21,24	10	7	27
WSD3093->=Hexadecasaccharides	3,5	283	20,49	9,25	5,75	30
Mean	**3,25**	**286,67**	**21,60**	**9,00**	**5,75**	**28,67**
SD	0,25	10,97	1,33	1,15	1,25	1,53
CV %	8	4	6	13	22	5
Variation versus not heparinoïd added PRP %	86	-77	-89	112	130	47
Variation versus Enoxaparine added PRP %	0	-47	-40	2	3	-13
DIA2844->=Hexadecasaccharides	3,25	208	15,66	10,25	7	31
DIA2844->=Hexadecasaccharides	3,5	168	11,45	9,5	6	31
DIA2844->=Hexadecasaccharides	3,25	166	12,57	8,75	5,5	29
Mean	**3,33**	**180,67**	**13,23**	**9,50**	**6,17**	**30,33**
SD	0,14	23,69	2,18	0,75	0,76	1,15
CV %	4	13	16	8	12	4
Variation versus not heparinoïd added PRP %	90	-86	-93	124	147	56
Variation versus Enoxaparine added PRP %	3	-67	-63	8	10	-8

Laboratoire LCL RECHERCHE CLINIQUE

TABLE IV

	Without Heparinoïd					
	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
	1,75	1322	182,78	4,5	2,75	27
	1,75	1300	203,28	4,25	2,5	17
	1,75	1278	197,72	4,25	2,5	17
	1,75	1140	188,99	4	2,25	17
Mean	**1,75**	**1260,00**	**193,19**	**4,25**	**2,50**	**19,50**
SD	0,00	81,99	9,10	0,20	0,20	5,00
CV %	0	7	5	5	8	26

	Heparinoïd concentration 10 µg/mL					
Tested molecule	With Hemoliance Recombiplastin 1/100 diluted					
	Lagtime	ETP	Peak	ttPeak	ttP - LT	startTail
Enoxaparine	4	480	34,61	12,25	8,25	33
Enoxaparine	3,75	430	27,29	10,5	6,75	33
Enoxaparine	3,75	456	34,3	8,75	5	30
Mean	**3,83**	**455,33**	**32,07**	**10,50**	**6,67**	**32,00**
SD	0,14	25,01	4,14	1,75	1,63	1,73
CV %	4	5	13	17	24	5
iation versus not heparinoïd added PRP %	119	-64	-83	147	57	64
WSD3093->=Hexadecasaccharides	3,5	248	17,16	9,5	6	31
WSD3093->=Hexadecasaccharides	3,5	186	12,5	10	6,5	32
WSD3093->=Hexadecasaccharides	3,5	215	13,81	10,25	6,75	34
Mean	**3,50**	**216,33**	**14,49**	**9,92**	**6,42**	**32,33**
SD	0,00	31,02	2,40	0,38	0,38	1,53
CV %	0	14	17	4	6	5
Variation versus not heparinoïd added PRP %	100	-83	-92	133	157	66
Variation versus Enoxaparine added PRP %	-9	-52	-55	-6	-4	1
DIA2844->=Hexadecasaccharides	4	113	8,15	10	6	28
DIA2844->=Hexadecasaccharides	4	126	9,35	11	7	29
DIA2844->=Hexadecasaccharides	4,5	108	7,79	11	6,5	31
Mean	**4,17**	**115,67**	**8,43**	**10,67**	**6,50**	**29,33**
SD	0,29	9,29	0,82	0,58	0,50	1,53
CV %	7	8	10	5	8	5
Variation versus not heparinoïd added PRP %	138	-91	-96	151	160	50
Variation versus Enoxaparine added PRP %	9	-75	-74	2	-3	-3

Laboratoire LCL RECHERCHE CLINIQUE

Figure 2



STRICTLY CONFIDENTIAL

Laboratoire LCL
RECHERCHE CLINIQUE

Figure 3



STRICTLY CONFIDENTIAL

Laboratoire LCL
RECHERCHE CLINIQUE

Figure 4



STRICTLY CONFIDENTIAL

Laboratoire LCL
RECHERCHE CLINIQUE

Figure 5

PEAK
Hemoliance Recombiplastin 1/100 diluted



STRICTLY CONFIDENTIAL

Laboratoire LCL
RECHERCHE CLINIQUE

Figure 6



STRICTLY CONFIDENTIAL

Laboratoire
LCL
RECHERCHE CLINIQUE

Figure 7



STRCTLY CONFIDENTIAL

Laboratoire LCL
RECHERCHE CLINIQUE

Figure 8

START TAIL
Hemoliance Recombiplastin 1/100 diluted



STRICTLY CONFIDENTIAL

Laboratoire LCL
RECHERCHE CLINIQUE

FIGURE 9

LAG TIME
Hemoliance Recombiplastin 1/100 diluted



STRICTLY CONFIDENTIAL

Laboratoire LCL
RECHERCHE CLINIQUE

FIGURE 10



STRICTLY CONFIDENTIAL

Laboratoire LCL
RECHERCHE CLINIQUE

FIGURE 11



STRICTLY CONFIDENTIAL

Laboratoire LCL RECHERCHE CLINIQUE

FIGURE 12



STRICTLY CONFIDENTIAL

Laboratoire LCL
RECHERCHE CLINIQUE

FIGURE 13

PEAK
Hemoliance Recombiplastin 1/100 diluted



STRICTLY CONFIDENTIAL

Laboratoire LCL
RECHERCHE CLINIQUE

FIGURE 14



STRICTLY CONFIDENTIAL

Laboratoire LCL
RECHERCHE CLINIQUE

FIGURE 15

TIME TO PEAK
Hemoliance Recombiplastin 1/100 diluted



STRICTLY CONFIDENTIAL

Laboratoire LCL
RECHERCHE CLINIQUE

FIGURE 16



STRICTLY CONFIDENTIAL

Laboratoire LCL
RECHERCHE CLINIQUE

FIGURE 17

TIME TO PEAK - LAG TIME
Hemoliance Recombiplastin 1/100 diluted



STRICTLY CONFIDENTIAL

Laboratoire LCL
RECHERCHE CLINIQUE

FIGURE 18



STRICTLY CONFIDENTIAL

Laboratoire LCL
RECHERCHE CLINIQUE

FIGURE 19



STRICTLY CONFIDENTIAL

Laboratoire LCL
RECHERCHE CLINIQUE

FIGURE 20



STRICTLY CONFIDENTIAL